Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Cell Line Sex - Both (118),Cell Line Sex - Male (64),Cell Line Sex - Female (40),Cell Line Ancestry - Caucasian (41),Cell Line Ancestry - Asian (28),Disease Modelling - Genetic Disorders (18),Disease Modelling - Arrhythmic (15),Disease Modelling - Ischemic Infarction (9),Disease Modelling - Dilated Cardiomyopathy (6),Disease Modelling - Hypertrophic Cardiomyopathy (6),Disease Modelling - Fibrotic (4),Pharmacological Intervention - Adrenaline (83),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Pharmacological Intervention - Isoproterenol (71),Pharmacological Intervention - QT-Prolonging Drugs (36),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Pharmacological Intervention - Verapamil (27),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Pharmacological Intervention - E4031 (22),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Pharmacological Intervention - Traditional Chemotherapy Agents (18),Pharmacological Intervention - Doxorubicin (17),Pharmacological Intervention - Class II Antiarrhythmics (β-Blockers for Arrhythmia) (14),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Pharmacological Intervention - Epinephrine (11),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Pharmacological Intervention - Positive Inotropes (9),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Pharmacological Intervention - Cisapride (8),Pharmacological Intervention - Ranolazine (7),Pharmacological Intervention - Lidocaine (7),Pharmacological Intervention - Carbamylcholine (6),Pharmacological Intervention - Propranolol (5),Pharmacological Intervention - Blebbistatin (5),Pharmacological Intervention - Metoprolol (5),Pharmacological Intervention - Caffeine (4),Pharmacological Intervention - Carbenoxolone (4)
Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Cell Line - BJ1 (7),Contractile Analysis Method - Force Transducer (27),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Pharmacological Intervention - Isoproterenol (71),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Pharmacological Intervention - Cisapride (8),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Wnt Induction - Wnt3a (3),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Electron Imaging - Transmission (62),3D Platform - Collagen (38),Deduced Culture Strategy - 3D Only (157),Metabolic Analysis Method - Genetic (3),Publication Year - 2014 (3),Contractile Analysis Method - Traction Force Microscopy (9),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),Contractile Analysis Method - Motion Tracking (93),Journal - Stem Cell Reports (23),2D Surface - Electrospun (13),Publication Year - 2021 (43),Journal - Tissue Eng Part A (4),Journal - Am J Physiol Heart Circ Physiol (4),Electrophysiology Analysis Method - Optical Mapping (39),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D Platform - Scaffold Free (43),3D Platform - Scaffold Free (43),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Cell Coculture - Endothelial Cell (35),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Publication Year - Post 2020 (122),Sacromere or Cellular Alignment Analysis - Yes (72),Wnt Inhibitor - XAV939 (24),Sacromere or Cellular Alignment Analysis - Yes (72),Contractile Analysis Method - Force Transducer (27),Contractile Analysis Method - Deflection (39),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Contractile Analysis Method - Motion Tracking (93),Journal - Biomater Sci (7),Electron Imaging - Transmission (62),Seeding Confluency 2D (%) - 80 to 84 (5),Metabolic Component - Dexamethasone (7),Journal - Biomater Sci (7),2D Surface - Micropatterned (27),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Seeding Confluency 2D (%) - 90 to 94 (12),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Cell Line - Rare (132),Purification Protocol - Cell Sorting (7),Disease Modelling - Arrhythmic (15),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Electrophysiology Analysis Method - Patch Clamp (59),Cell Line Ancestry - Caucasian (41),Cell Line Ancestry - Asian (28),Cell Line - IMR90 (19),Cell Line Sex - Both (118),Cell Line - WTC11 (30),Coating for Replating - Laminin (5),Coating for Replating - Laminin (5),Metabolic Component Category - Sugars and Carbohydrates (9),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),hiPSC-CM Purification Duration (days) - <3 days (31),Journal - Nat Commun (13),Calcium Handling Analysis Method - Visual (104),Calcium Handling Analysis Method - Visual (104),Calcium Handling Analysis Method - Visual (104),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Journal - Toxicological Sciences (4),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Journal - Sci Rep (24),Journal - Sci Rep (24),Electrophysiology Analysis Method - Microelectrode (31),Number of Cell Lines - 3 (29),Cell Line - iCell2 (8),Cell Line - iCell2 (8),Cell Line - iCell (47),Cell Line - Cor.4U (16),Journal - Toxicological Sciences (4),Journal - Nat Commun (13),Cell Line - iCell (47),Cell Line - iCell (47),Number of Cell Lines - 3 (29),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Wnt Inhibitor Duration (days) - 4 days (19),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Journal - Tissue Eng Part C Methods (6),Electrophysiology Analysis Method - Microelectrode (31),Metabolic Component - T3 (14),Publication Year - 2015 (19)
Metabolic Component Category - Signaling Pathway Regulators (6),Number of Cell Lines - 2 (50),Contractile Analysis Method - Force Transducer (27),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Contractile Analysis Method - Deflection (39),Calcium Handling Analysis Method - Visual (104),Journal - Cell Stem Cell (6),Seeding Confluency (%) - 80 to 84 (12),Publication Year - 2017 (43),Disease Modelling - Genetic Disorders (18),Publication Year - 2021 (43),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Cell Line - 201B6 (3),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Contractile Analysis Method - Deflection (39),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Sacromere or Cellular Alignment Analysis - Yes (72),Cell Line - IMR90 (19),New Media for Maturation - RPMI-1640 (30),hiPSC Matrix Coating - Matrigel (163),hiPSC Matrix Coating - Geltrex (33),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Publication Year - 2022 (20),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Pharmacological Intervention - Adrenaline (83),Insulin Start Day - 5 (14),Electron Imaging - Scanning (22),Gene Analysis Method - RNA (169),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),3D Platform - Collagen (38),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Contractile Analysis Method - Rare (7),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Deduced Culture Strategy - 3D Only (157),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Coculture - Cardiomyocyte (157),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Cell Coculture - Stromal Cell (78),Publication Year - 2020 (51),Insulin Start Day - 7 (85),Sacromere or Cellular Alignment Analysis - Yes (72),Journal - Am J Physiol Heart Circ Physiol (4),Journal - J Tissue Eng (4),Publication Year - 2021 (43),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Line - 201B6 (3),3D Tissue Media - RPMI-1640 (72),Sacromere or Cellular Alignment Analysis - Yes (72),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Handling Analysis Method - Visual (104),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),hiPSC Backbone Media - StemFlex (5),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Sacromere or Cellular Alignment Analysis - Yes (72),Gene Analysis Method - Rare (5),Seeding Confluency 3D (%) - 70 to 79 (3),2D Surface - Microelectrode Array (9),Insulin Start Day - 9 (10),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Insulin Start Day - 2 (4),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Journal - Cell Stem Cell (6),Cell Line - WTC11 (30),Cell Line - WTC11 (30),Cell Line Ancestry - Caucasian (41),Cell Line - PGP1 (11),Cell Line Sex - Male (64),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Electrophysiology Analysis Method - Genetic (3),Publication Year - 2024 (7),2D Surface - Micropatterned (27),Insulin Start Day - 7 (85),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Contractile Analysis Method - Motion Tracking (93),2D Surface - Microelectrode Array (9),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Wnt Inhibitor - KY02111 (7),Maturation Strategy - Electrical (39),Cell Line - iCell (47),Cell Line - iCell (47),hiPSC-CM Maturation Media - iCell Maintenance (83),Cell Line - iCell (47),Journal - Toxicological Sciences (4),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Toxicological Sciences (4),Number of Cell Lines - 3 (29),Journal - Cell Rep (6),Cell Line - iCell (47),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Cor.4U (16),Insulin Start Day - 5 (14),3D Platform - Polyethylene Glycol (8),hiPSC-CM Media Supplement - HEPES (16),Cell Line - iCell (47),Metabolic Component - Dexamethasone (7),Electrophysiology Analysis Method - Optical Mapping (39)
T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),3D Tissue Media - Iscove (5),Cell Line - BJ1 (7),Metabolic Component - Palmitic Acid (11),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),hiPSC Matrix Coating - Rare (8),Calcium Handling Analysis Method - Visual (104),Coating for Replating - Gelatin (43),Disease Modelling - Arrhythmic (15),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),3D Stromal Cell Source - hiPSC-MuralC (3),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - Stem Cell Reports (23),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Contractile Analysis Method - Force Transducer (27),Electron Imaging - Transmission (62),Seeding Confluency (%) - 90 to 94 (26),2D Surface - Micropatterned (27),hiPSC Matrix Coating - Vitronectin (10),Journal - ACS Appl Mater Interfaces (4),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Handling Analysis Method - Visual (104),Coating for Replating - Rare (6),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Publication Year - 2018 (45),Maturation Strategy - Mechanical (36),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Number of Cell Lines - 2 (50),Publication Year - 2018 (45),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Deduced Culture Strategy - 3D Only (157),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Coculture - Cardiomyocyte (157),Cell Coculture - Stromal Cell (78),Deduced Culture Strategy - 3D Only (157),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Cell Coculture - Cardiomyocyte (157),3D Stromal Cell Source - Stromal Cell (35),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Cell Line - IMR90 (19),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC-CM Media Supplement - FBS (16),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Maturation Strategy - Tension (64),Metabolic Component - Dexamethasone (7),3D Platform - Collagen (38),Publication Year - 2021 (43),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Calcium Handling Analysis Method - Genetic (23),Metabolic Component - T3 (14),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Pharmacological Intervention - Cisapride (8),Calcium Handling Analysis Method - Visual (104),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Differentiation Purity Assessment - IHC a-actinin (8),Cell Line - C25 (6),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC-CM Maturation Media - RPMI-1640 (153),Journal - Int J Mol Sci (3),Number of Cell Lines - 4 (11),Cell Line - IMR90 (19),Cell Line - DF19-9-11T.H (16),Cell Line - 201B7 (9),Cell Line Sex - Female (40),Cell Line Sex - Both (118),Electrophysiology Analysis Method - Genetic (3),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Metabolic Analysis Method - Genetic (3),hiPSC Matrix Coating - MEF feeder cells (8),Cell Line - PGP1 (11),3D Stromal Cell Source - Human Fibroblast (38),3D Tissue Media - DMEM (53),3D Tissue Media - DMEM (53),Electrophysiology Analysis Method - Microelectrode (31),Cell Line - iCell (47),Cell Line - iCell (47),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - Cellapy (4),Journal - Int J Mol Sci (3),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),Number of Cell Lines - 3 (29),hiPSC-CM Maturation Media - iCell Maintenance (83),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Journal - Toxicological Sciences (4),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Journal - Toxicological Sciences (4),hiPSC-CM Maturation Media - iCell Maintenance (83),Disease Modelling - Arrhythmic (15),Number of Cell Lines - 3 (29),Number of Cell Lines - 4 (11),Wnt Inhibitor Duration (days) - >6 days (12),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),hiPSC-CM Maturation Media - iCell Maintenance (83),Cell Line - Cor.4U (16),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Seeding Confluency (%) - 85 to 89 (43),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Day of Insulin Addition - not 25 (3),Journal - Cell Rep (6),Insulin Start Day - 2 (4),Cell Line - iCell (47)
Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Journal - Circulation (11),Purification Protocol - Glucose and Lactate (85),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Journal - Cell Stem Cell (6),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Seeding Confluency 2D (%) - 80 to 84 (5),Journal - PNAS (3),Coating for Replating - Fibronectin (32),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Coating for Replating - Rare (6),Maturation Strategy - Other Cells (80),Contractile Analysis Method - Rare (7),Journal - Stem Cell Reports (23),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Disease Modelling - Hypertrophic Cardiomyopathy (6),Cell Coculture - Cardiomyocyte (157),Cell Coculture - Cardiomyocyte (157),2D Surface - ECM-coated (115),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Journal - Stem Cell Res Ther (3),Journal - PLoS One (9),hiPSC Backbone Media - Essential 8 (82),Wnt Induction - StemCell Diff Kit (4),Pharmacological Intervention - Phenylephrine (3),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Purification Duration (days) - 5 days (6),Electron Imaging - Transmission (62),Publication Year - 2017 (43),hiPSC Backbone Media - Conditioned (12),Cell Line - Cor.4U (16),Journal - Nat Biomed Eng (5),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Contractile Analysis Method - Rare (7),3D Tissue Media - Commercial Kit (21),3D Tissue Media - Commercial Kit (21),Deduced Culture Strategy - 3D Only (157),Maturation Strategy - Other Cells (80),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),Cell Coculture - Stromal Cell (78),Deduced Culture Strategy - 3D Only (157),Maturation Strategy - Other Cells (80),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Wnt Inhibitor Duration (days) - 5 days (6),Number of Cell Lines - 2 (50),Cell Line - IMR90 (19),Cell Line Sex - Both (118),hiPSC-CM Media Supplement - Lipid Mix (5),3D Tissue Media - MEM-α (60),Maturation Strategy - Tension (64),hiPSC-CM Purification Duration (days) - 4 days (29),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),2D Surface - Decellularized ECM (3),Electrophysiology Analysis Method - Patch Clamp (59),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Seeding Confluency (%) - 80 to 84 (12),Journal - Circ Res (5),Calcium Handling Analysis Method - Visual (104),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Disease Modelling - Dilated Cardiomyopathy (6),2D Surface - Decellularized ECM (3),Publication Year - 2016 (32),Electrophysiology Analysis Method - Optical Mapping (39),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Journal - Int J Mol Sci (3),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Seeding Confluency (%) - 70 to 79 (11),Electron Imaging - Transmission (62),Cell Line Ancestry - Asian (28),Wnt Induction - CHIR99021 (184),Wnt Induction - BMP4 (74),Cell Line - 201B7 (9),Calcium Handling Analysis Method - Genetic (23),Cell Line - Rare (132),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Seeding Confluency 3D (%) - 90 to 94 (13),Wnt Inhibitor - BMP4 (7),Contractile Analysis Method - Traction Force Microscopy (9),3D Stromal Cell Source - Cardiac Fibroblast (32),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Contractile Analysis Method - Motion Tracking (93),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - Cor.4U (16),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - Cellapy (4),Number of Cell Lines - 4 (11),Wnt Inhibitor - Others (9),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Coating for Replating - Matrigel (65),Journal - Biomaterials (16),Wnt Inhibitor Duration (days) - >6 days (12),Journal - Nat Commun (13),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Cell Rep (6),Disease Modelling - Arrhythmic (15),Gene Analysis Method - RNA (169),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Disease Modelling - Arrhythmic (15),Coating for Replating - Gelatin (43),Cell Line - iCell (47),Journal - Int J Mol Sci (3),Cell Line - SCVI-273 (8),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Day of Insulin Addition - not 9 (3),Coating for Replating - Rare (6),hiPSC-CM Maturation Media - F12 (10),hiPSC-CM Media Supplement - iCell Maintenance Medium (41)
Electrophysiology Analysis Method - Patch Clamp (59),Coating for Replating - Rare (6),Maturation Strategy - Tension (64),Day of Insulin Addition - not 24 (9),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Gene Analysis Method - Rare (5),Purification Protocol - Metabolic (8),Journal - Nano Lett (3),Calcium Handling Analysis Method - Visual (104),Journal - Biosens Bioelectron (4),Maturation Strategy - ECM (21),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),hiPSC Backbone Media - Conditioned (12),Journal - Stem Cell Reports (23),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Tissue Eng Part A (4),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Metabolic Analysis Method - Mitochondrial (4),Journal - Biomaterials (16),Purification Protocol - Glucose and Lactate (85),Calcium Handling Analysis Method - Visual (104),Coating for Replating - Fibronectin (32),3D Stromal Cell Source - Stromal Cell (35),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Calcium Handling Analysis Method - Visual (104),3D Tissue Media - High-glucose DMEM (9),Cell Line - ATCC (5),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Maturation Media - StemPro-34 (14),hiPSC-CM Media Supplement - Rare (5),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Cell Coculture - Cardiomyocyte (157),Cell Coculture - Cardiomyocyte (157),3D Tissue Media - RPMI-1640 (72),Cell Coculture - Endothelial Cell (35),Maturation Strategy - Tension (64),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Cell Coculture - Cardiomyocyte (157),Sacromere or Cellular Alignment Analysis - Yes (72),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Electron Imaging - Transmission (62),hiPSC Backbone Media - mTeSR (106),hiPSC-CM Backbone Media - DMEM (18),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),Contractile Analysis Method - Deflection (39),3D Stromal Cell Source - Dermal Fibroblast (7),Contractile Analysis Method - Force Transducer (27),3D Platform - Gelatin (6),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Journal - Tissue Eng Part A (4),hiPSC Matrix Coating - Vitronectin (10),Contractile Analysis Method - Deflection (39),Journal - Rare (104),Insulin Start Day - 0 (7),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),hiPSC-CM Media Supplement - Albumin (28),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Pharmacological Intervention - E4031 (22),Number of Cell Lines - 4 (11),hiPSC-CM Backbone Media - RPMI-1640 (167),Journal - Am J Physiol Heart Circ Physiol (4),Metabolic Component - Palmitic Acid (11),Cell Line - DF19-9-11T.H (16),Cell Line - PGP1 (11),Seeding Confluency 2D (%) - Rare (13),Seeding Confluency (%) - Rare (43),3D Tissue Media - RPMI-1640 (72),2D Surface - ECM-coated (115),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),Metabolic Component - B27 (3),Number of Cell Lines - 3 (29),Journal - Circ Res (5),Number of Cell Lines - 2 (50),Contractile Analysis Method - Motion Tracking (93),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),3D Tissue Media - DMEM (53),Electrophysiology Analysis Method - Patch Clamp (59),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),hiPSC-CM Maturation Media - iCell Maintenance (83),Publication Year - 2016 (32),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Journal - Toxicological Sciences (4),Journal - Toxicological Sciences (4),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Cell Line - Cor.4U (16),Electrophysiology Analysis Method - Microelectrode (31),Electrophysiology Analysis Method - Microelectrode (31),Cell Line - Cor.4U (16),Journal - Acta Biomater (10),3D Tissue Media - Commercial Kit (21),Electrophysiology Analysis Method - Optical Mapping (39),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Cor.4U (16),Journal - Toxicological Sciences (4),Number of Cell Lines - >5 (9),3D Tissue Media - Iscove (5),Calcium Handling Analysis Method - Visual (104),3D Tissue Media - Growth Factor (12),Journal - Sci Rep (24),Wnt Inhibitor - Wnt-C59 (30),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24)
Metabolic Analysis Method - Seahorse (35),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Day of Insulin Addition - not 23 (10),Cell Line Ancestry - Asian (28),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Pharmacological Intervention - Adrenaline (83),hiPSC Matrix Coating - Geltrex (33),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Number of Cell Lines - 3 (29),Maturation Strategy - Tension (64),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Number of Cell Lines - 3 (29),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Pharmacological Intervention - Caffeine (4),Deduced Culture Strategy - 3D Only (157),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Sacromere or Cellular Alignment Analysis - Yes (72),Maturation Strategy - Cell Alignment (59),Purification Protocol - Glucose and Lactate (85),Maturation Strategy - Mechanical (36),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),Seeding Confluency (%) - 80 to 84 (12),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),3D Tissue Media - iCell Maintenance (12),Wnt Inhibitor - IWR (56),Wnt Induction Duration (days) - 3 days (38),Journal - ACS Appl Mater Interfaces (4),hiPSC-CM Backbone Media - StemPro-34 (14),Journal - Tissue Eng Part A (4),Publication Year - 2019 (57),Insulin Start Day - 0 (7),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Platform - Scaffold Free (43),3D Stromal Cell Source - Stromal Cell (35),3D Platform - Fibrin (50),Maturation Strategy - Other Cells (80),3D Tissue Media - RPMI-1640 (72),3D Stromal Cell Source - Human Fibroblast (38),Maturation Strategy - Mechanical (36),hiPSC-CM Backbone Media - Commercial CM Kit (12),Insulin Start Day - 7 (85),Insulin Start Day - 7 (85),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),hiPSC-CM Backbone Media - StemPro-34 (14),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),3D Tissue Media - RPMI-1640 (72),Wnt Induction - Wnt3a (3),Pharmacological Intervention - Cardiotoxic Agents (3),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Sacromere or Cellular Alignment Analysis - Yes (72),3D Stromal Cell Source - Stromal Cell (35),Cell Line Sex - Both (118),Calcium Handling Analysis Method - Visual (104),Maturation Strategy - Other Cells (80),Calcium Handling Analysis Method - Visual (104),3D Platform - Gelatin (6),Metabolic Analysis Method - Genetic (3),Coating for Replating - Gelatin (43),Journal - Stem Cells (11),hiPSC Matrix Coating - Matrigel (163),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Cell Line - C25 (6),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),hiPSC Matrix Coating - Matrigel (163),3D Tissue Media - RPMI-1640 (72),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),hiPSC Backbone Media - mTeSR (106),Publication Year - 2022 (20),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Journal - Am J Physiol Heart Circ Physiol (4),Maturation Strategy - Metabolic (33),Insulin Start Day - 7 (85),Coating for Replating - Matrigel (65),3D Tissue Media - Commercial Kit (21),Cell Coculture - Cardiomyocyte (157),Electrophysiology Analysis Method - Optical Mapping (39),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Number of Cell Lines - 4 (11),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - iCell (47),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - Cor.4U (16),Journal - Biomaterials (16),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Publication Year - Late-2010s (196),Calcium Handling Analysis Method - Visual (104),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Lab Chip (4),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Cell Line Ancestry - Caucasian (41),Coating for Replating - Matrigel (65),Number of Cell Lines - 3 (29),Publication Year - 2020 (51),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Publication Year - 2017 (43),Seeding Confluency 2D (%) - 85 to 89 (26),Cell Line - 253G1 (10),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Metabolic Component Category - Hormonal Stimulation (14),Journal - Nano Lett (3)
Journal - Tissue Eng Part C Methods (6),Journal - Acta Biomater (10),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),2D Surface - Hydrogel (17),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Metabolic Component - Palmitic Acid (11),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Day of Insulin Addition - not 11 (5),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),hiPSC-CM Media Supplement - L-glutamine (19),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Disease Modelling - Arrhythmic (15),hiPSC-CM Media Supplement - Rare (5),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Gene Analysis Method - RNA (169),3D Stromal Cell Source - Human Fibroblast (38),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Calcium Handling Analysis Method - Visual (104),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Cell Line Ancestry - Asian (28),hiPSC-CM Purification Duration (days) - 4 days (29),Insulin Start Day - 7 (85),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Electron Imaging - Scanning (22),Day of Insulin Addition - not 11 (5),Pharmacological Intervention - Verapamil (27),Journal - Tissue Eng Part A (4),Journal - Cell Stem Cell (6),Number of Cell Lines - 2 (50),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Disease Modelling - Arrhythmic (15),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Cell Coculture - Endothelial Cell (35),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Maturation Strategy - Tension (64),Cell Coculture - Cardiomyocyte (157),Contractile Analysis Method - Deflection (39),Deduced Culture Strategy - 3D Only (157),Seeding Confluency 3D (%) - Rare (26),Cell Coculture - Endothelial Cell (35),Disease Modelling - Hypertrophic Cardiomyopathy (6),2D Surface - Micropatterned (27),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),hiPSC-CM Maturation Media - DMEM (35),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),hiPSC-CM Media Supplement - HEPES (16),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Platform - Matrigel (33),Day of Insulin Addition - not 23 (10),Cell Line - 253G1 (10),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Journal - Nano Lett (3),Seeding Confluency 3D (%) - 80 to 84 (5),hiPSC-CM Backbone Media - Commercial CM Kit (12),Seeding Confluency 2D (%) - 70 to 79 (6),Publication Year - 2018 (45),3D Stromal Cell Source - Stromal Cell (35),Cell Line Sex - Both (118),Journal - Cell Stem Cell (6),Journal - Tissue Eng Part C Methods (6),Pharmacological Intervention - Caffeine (4),Publication Year - 2020 (51),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Purification Protocol - Cell Sorting (7),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),3D Stromal Cell Source - Rare (4),Cell Line - 201B7 (9),Day of Insulin Addition - Known (177),Wnt Induction - Activin A (80),Cell Line - C25 (6),hiPSC Backbone Media - Essential 8 (82),Coating for Replating - Gelatin (43),Insulin Start Day - 11 (3),Pharmacological Intervention - Epinephrine (11),hiPSC-CM Purification Duration (days) - <3 days (31),Journal - ACS Appl Mater Interfaces (4),Journal - Biomaterials (16),Electrophysiology Analysis Method - Optical Mapping (39),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Electrophysiology Analysis Method - Optical Mapping (39),Coating for Replating - Gelatin (43),2D Surface - Decellularized ECM (3),3D Platform - Scaffold Free (43),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Journal - Rare (104),Publication Year - Late-2010s (196),Electrophysiology Analysis Method - Optical Mapping (39),Coating for Replating - Matrigel (65),Cell Line - iCell (47),Number of Cell Lines - 4 (11),hiPSC-CM Purification Duration (days) - 3 days (13),Journal - Lab Chip (4),hiPSC-CM Backbone Media - iCell Maintenance (86),Electrophysiology Analysis Method - Microelectrode (31),Number of Cell Lines - >5 (9),Publication Year - 2019 (57),Cell Line - iCell (47),Maturation Strategy - ECM (21),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),hiPSC-CM Maturation Media - Cor.4U Complete (6),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Cell Line - IMR90 (19),Publication Year - 2020 (51),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D Tissue Media - Iscove (5)
Electron Imaging - Transmission (62),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Metabolic Component - Fatty Acid (13),hiPSC-CM Purification Duration (days) - >9 days (5),Cell Line - 253G1 (10),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Differentiation Purity Assessment - IHC cTnT (7),Publication Year - 2016 (32),Sacromere or Cellular Alignment Analysis - Yes (72),Electron Imaging - Transmission (62),Journal - Rare (104),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Calcium Handling Analysis Method - Visual (104),Insulin Withdrawal Duration (days) - 4 days (18),Metabolic Component - Dexamethasone (7),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Stromal Cell Source - hiPSC-MuralC (3),Journal - J Mol Cell Cardiol (4),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),hiPSC Matrix Coating - Matrigel (163),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),hiPSC-CM Purification Duration (days) - 6 days (10),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),hiPSC Backbone Media - StemFit (5),Pharmacological Intervention - T3 (3),Seeding Confluency 3D (%) - 80 to 84 (5),2D Surface - Electrospun (13),Journal - ACS Appl Mater Interfaces (4),Wnt Inhibitor - XAV939 (24),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Disease Modelling - Ischemic Infarction (9),Disease Modelling - Arrhythmic (15),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),3D SC Ratio (CM-EC-SC) Quantiles - Q3 (>0 and ≤0) (74),3D Platform - Fibrin (50),3D Stromal Cell Source - Human Fibroblast (38),Cell Coculture - Stromal Cell (78),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),3D Platform - Fibrin (50),Deduced Culture Strategy - 3D Only (157),hiPSC-CM Purification Duration (days) - <3 days (31),Metabolic Component - T3 (14),Calcium Handling Analysis Method - Visual (104),Seeding Confluency (%) - 70 to 79 (11),Journal - J Tissue Eng Regen Med (3),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Metabolic Component - IGF-1 (3),Journal - Biosens Bioelectron (4),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Contractile Analysis Method - Motion Tracking (93),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Calcium Handling Analysis Method - Visual (104),Metabolic Component - IGF-1 (3),3D Tissue Media - Iscove (5),Pharmacological Intervention - Isoproterenol (71),3D Platform - Scaffold Free (43),Cell Coculture - Stromal Cell (78),Day of Insulin Addition - not 15 (16),Journal - Am J Physiol Heart Circ Physiol (4),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Publication Year - 2018 (45),Journal - Biosens Bioelectron (4),Journal - Cell Stem Cell (6),Pharmacological Intervention - Caffeine (4),Publication Year - 2015 (19),Coating for Replating - Laminin (5),Disease Modelling - Genetic Disorders (18),Day of Insulin Addition - Known (177),Wnt Inhibitor - IWP (112),Seeding Confluency (%) - Rare (43),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Purification Protocol - Cell Sorting (7),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Differentiation Purity Assessment - Rare (3),3D Stromal Cell Source - Mesenchymal Stem Cell (12),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Contractile Analysis Method - Deflection (39),Contractile Analysis Method - Deflection (39),3D Platform - Extracellular Scaffold (18),3D Platform - Scaffold Free (43),Cell Line - iCell (47),Cell Line - Cor.4U (16),3D Stromal Cell Source - Cardiac Fibroblast (32),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),hiPSC-CM Backbone Media - iCell Maintenance (86),hiPSC-CM Backbone Media - iCell Maintenance (86),hiPSC-CM Backbone Media - iCell Maintenance (86),Number of Cell Lines - 3 (29),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Visual (104),Journal - Nat Commun (13),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Toxicological Sciences (4),Journal - Sci Rep (24),3D Platform - Fibrin (50),Cell Line - Cor.4U (16),hiPSC-CM Backbone Media - iCell Maintenance (86),Journal - Sci Rep (24),3D Tissue Media - Rare (13),Insulin Start Day - 3 (5),Journal - Biomaterials (16),Journal - ACS Appl Mater Interfaces (4),Number of Cell Lines - 3 (29),Wnt Inhibitor - bFGF (8),3D Stromal Cell Source - hiPSC-CardiacF (8)
MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),3D Platform - Collagen (38),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Metabolic Component Category - Sugars and Carbohydrates (9),hiPSC-CM Purification Duration (days) - 3 days (13),Publication Year - 2015 (19),Insulin Start Day - 0 (7),Cell Line - BJ RiPS (4),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),hiPSC-CM Media Supplement - Polyvinylalchohol (6),New Media for Maturation - RPMI-1640 (30),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Calcium Handling Analysis Method - Rare (4),3D Stromal Cell Source - Cardiac Fibroblast (32),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Cell Coculture - Stromal Cell (78),3D Platform - Fibrin (50),Coating for Replating - Matrigel (65),hiPSC Backbone Media - Conditioned (12),Journal - Stem Cell Reports (23),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Wnt Inhibitor - IWR (56),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Publication Year - Post 2020 (122),Metabolic Component Category - Metabolic Modulation (20),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),hiPSC Backbone Media - Rare (19),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),hiPSC-CM Media Supplement - L-glutamine (19),Insulin Start Day - 0 (7),3D Stromal Cell Source - Stromal Cell (35),Maturation Strategy - Mechanical (36),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Electron Imaging - Transmission (62),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Deduced Culture Strategy - 3D Only (157),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Cell Coculture - Cardiomyocyte (157),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Contractile Analysis Method - Traction Force Microscopy (9),Cell Line - Gibco episomal (10),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Publication Year - 2016 (32),Publication Year - 2018 (45),Disease Modelling - Genetic Disorders (18),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),3D Platform - Fibrin (50),3D Stromal Cell Source - hiPSC-MuralC (3),3D Platform - Fibronectin (3),3D Platform - Polyethylene Glycol (8),Electron Imaging - Scanning (22),Maturation Strategy - Other Cells (80),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Calcium Handling Analysis Method - Visual (104),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Seeding Confluency 2D (%) - 70 to 79 (6),2D Surface - Decellularized ECM (3),Insulin Start Day - 1 (19),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),Insulin Start Day - After 11 (7),Day of Insulin Addition - not 9 (3),Pharmacological Intervention - QT-Prolonging Drugs (36),2D Surface - Electrospun (13),Coating for Replating - Synthemax (3),Journal - PLoS One (9),Metabolic Component - Dexamethasone (7),hiPSC Backbone Media - Embryonic Stem Cell (127),hiPSC Matrix Coating - Matrigel (163),Cell Line - SCVI-273 (8),Wnt Induction - Activin A (80),hiPSC Matrix Coating - Matrigel (163),Electrophysiology Analysis Method - Patch Clamp (59),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),Metabolic Component - Albumax (3),3D Tissue Media - Iscove (5),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Insulin Start Day - After 11 (7),Deduced Culture Strategy - 3D Only (157),hiPSC Backbone Media - Essential 8 (82),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Maturation Media - iCell Maintenance (83),2D Surface - Decellularized ECM (3),3D Platform - Scaffold Free (43),Seeding Confluency 2D (%) - 80 to 84 (5),2D Surface - Microelectrode Array (9),Journal - Toxicological Sciences (4),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Purification Duration (days) - 8 days (4),hiPSC-CM Backbone Media - iCell Maintenance (86),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),hiPSC-CM Backbone Media - iCell Maintenance (86),Publication Year - 2017 (43),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - iCell (47),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),3D Stromal Cell Source - Human Fibroblast (38),Number of Cell Lines - 4 (11),2D Surface - Microelectrode Array (9),Differentiation Purity Assessment - Visual Inspection (6),Number of Cell Lines - 4 (11),hiPSC-CM Purification Duration (days) - 5 days (6),Wnt Inhibitor - IWP (112),Journal - Am J Physiol Heart Circ Physiol (4),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Cell Line - Cellapy (4),Publication Year - 2020 (51)
hiPSC-CM Media Supplement - Rare (5),Gene Analysis Method - RNA (169),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Day of Insulin Addition - not 22 (12),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Metabolic Analysis Method - Seahorse (35),Publication Year - 2024 (7),Maturation Strategy - ECM (21),Seeding Confluency 3D (%) - 90 to 94 (13),Journal - Circ Res (5),Electrophysiology Analysis Method - Optical Mapping (39),Coating for Replating - Synthemax (3),2D Surface - ECM-coated (115),3D Platform - Collagen (38),Publication Year - 2019 (57),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Cell Line - BJ1 (7),Cell Line Ancestry - Caucasian (41),Publication Year - 2022 (20),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Contractile Analysis Method - Deflection (39),Contractile Analysis Method - Traction Force Microscopy (9),Seeding Confluency (%) - 85 to 89 (43),Cell Line - ATCC (5),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Biomater Sci (7),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - J Biomed Mater Res A (3),3D Tissue Media - iCell Maintenance (12),Seeding Confluency (%) - 85 to 89 (43),Wnt Induction - Activin A (80),Seeding Confluency 3D (%) - 70 to 79 (3),Calcium Handling Analysis Method - Rare (4),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Metabolic Component - Palmitic Acid (11),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Seeding Confluency 3D (%) - Rare (26),3D Platform - Collagen (38),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D Platform - Scaffold Free (43),3D Stromal Cell Source - Cardiac Fibroblast (32),Journal - Acta Biomater (10),Disease Modelling - Dilated Cardiomyopathy (6),3D Tissue Media - RPMI-1640 (72),Seeding Confluency 2D (%) - 80 to 84 (5),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),hiPSC-CM Maturation Media - StemPro-34 (14),3D Platform - Fibrin (50),Seeding Confluency 3D (%) - 90 to 94 (13),3D Stromal Cell Source - Stromal Cell (35),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Seeding Confluency (%) - 80 to 84 (12),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Pharmacological Intervention - Carbamylcholine (6),Electrophysiology Analysis Method - Optical Mapping (39),Seeding Confluency (%) - 80 to 84 (12),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Insulin Start Day - 2 (4),Wnt Inhibitor - Rare (3),hiPSC Backbone Media - Rare (19),New Media for Maturation - Commercial Kit (5),Journal - Tissue Eng Part C Methods (6),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Cell Line - PGP1 (11),Purification Protocol - Glucose and Lactate (85),Number of Cell Lines - 2 (50),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),Day of Insulin Addition - not 20 (15),Cell Line - iCell (47),hiPSC-CM Purification Duration (days) - 4 days (29),Wnt Inhibitor Duration (days) - 6 days (4),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Journal - Nat Biomed Eng (5),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),hiPSC Backbone Media - Essential 8 (82),Cell Coculture - Cardiomyocyte (157),Cell Coculture - Cardiomyocyte (157),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),hiPSC-CM Maturation Media - Rare (9),Journal - Nat Commun (13),hiPSC-CM Maturation Media - iCell Maintenance (83),Maturation Strategy - ECM (21),Journal - Int J Mol Sci (3),Number of Cell Lines - 4 (11),3D Platform - Scaffold Free (43),2D Surface - ECM-coated (115),Electrophysiology Analysis Method - Optical Mapping (39),Cell Line - iCell (47),Publication Year - 2017 (43),Disease Modelling - Ischemic Infarction (9),2D Surface - Microelectrode Array (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),2D Surface - Decellularized ECM (3),Electrophysiology Analysis Method - Microelectrode (31),Coating for Replating - Gelatin (43),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Handling Analysis Method - Genetic (23),Journal - Acta Biomater (10),Publication Year - 2018 (45),Publication Year - 2016 (32),Coating for Replating - Synthemax (3),hiPSC-CM Maturation Media - iCell Maintenance (83),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6)
Journal - Biosens Bioelectron (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),3D Tissue Media - Growth Factor (12),Seeding Confluency 3D (%) - 95 to 100 (13),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Purification Protocol - Glucose and Lactate (85),3D Platform - Fibronectin (3),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),hiPSC Backbone Media - DMEM (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Pharmacological Intervention - Cardioselective Ca Channel Blockers (31),Metabolic Analysis Method - Seahorse (35),Wnt Induction - Rare (4),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),hiPSC-CM Purification Duration (days) - 4 days (29),Journal - Nat Biomed Eng (5),Number of Cell Lines - 2 (50),3D Platform - Fibrin (50),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Publication Year - 2018 (45),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),Journal - Stem Cells Int (3),Insulin Start Day - 6 (20),Maturation Strategy - Tension (64),Seeding Confluency 3D (%) - 90 to 94 (13),Metabolic Component - IGF-1 (3),Maturation Strategy - ECM (21),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),2D Surface - Micropatterned (27),Coating for Replating - Gelatin (43),hiPSC Backbone Media - DMEM (10),Journal - Biomater Sci (7),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Tissue Eng Part A (4),Calcium Handling Analysis Method - Rare (4),3D Tissue Media - Growth Factor (12),Contractile Analysis Method - Motion Tracking (93),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),3D Stromal Cell Source - Stromal Cell (35),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Electrophysiology Analysis Method - Patch Clamp (59),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Maturation Strategy - Metabolic (33),3D Platform - Fibrin (50),Seeding Confluency (%) - Rare (43),3D Tissue Media - DMEM (53),Cell Coculture - Stromal Cell (78),Maturation Strategy - Tension (64),Journal - Biomaterials (16),3D Tissue Media - DMEM (53),Maturation Strategy - Cell Alignment (59),Insulin Start Day - 7 (85),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Contractile Analysis Method - Motion Tracking (93),Calcium Handling Analysis Method - Genetic (23),Wnt Inhibitor - IWR (56),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Publication Year - 2024 (7),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Pharmacological Intervention - Class Ic Antiarrhythmics (Na+ Channel Blockers - Strong Blockade) (9),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Wnt Induction - Rare (4),Seeding Confluency (%) - Rare (43),hiPSC Matrix Coating - EBs (18),Journal - Nat Commun (13),Wnt Induction - CHIR99021 (184),Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),Journal - Stem Cell Res (8),Cell Line Sex - Male (64),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),3D Tissue Media - RPMI-1640 (72),Journal - Circulation (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Maturation Strategy - Mechanical (36),hiPSC-CM Backbone Media - iCell Maintenance (86),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Publication Year - 2016 (32),3D Tissue Media - MEM-α (60),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Cell Line - Cellapy (4),Number of Cell Lines - 4 (11),2D Surface - Decellularized ECM (3),Number of Cell Lines - 4 (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Journal - Nat Commun (13),3D Tissue Media - Rare (13),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Publication Year - 2021 (43),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),2D Surface - ECM-coated (115),Calcium Handling Analysis Method - Visual (104),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Int J Mol Sci (3),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Contractile Analysis Method - Deflection (39),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Number of Cell Lines - 3 (29),Differentiation Purity Assessment - IHC a-actinin (8),Disease Modelling - Arrhythmic (15),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),hiPSC Matrix Coating - Vitronectin (10),Seeding Confluency (%) - 95 to 100 (23),2D Surface - Hydrogel (17),hiPSC-CM Media Supplement - Albumin (28),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8)
Wnt Inhibitor - IWP (112),Disease Modelling - Hypertrophic Cardiomyopathy (6),hiPSC Backbone Media - DMEM (10),Journal - Circulation (11),Journal - Tissue Eng Part C Methods (6),Metabolic Component Category - Fatty Acids and Lipids (21),3D Tissue Media - MEM-α (60),Journal - Stem Cells (11),hiPSC Matrix Coating - MEF feeder cells (8),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Wnt Induction - Rare (4),Number of Cell Lines - 3 (29),hiPSC-CM Backbone Media - Commercial CM Kit (12),Sacromere or Cellular Alignment Analysis - Yes (72),Disease Modelling - Genetic Disorders (18),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Cell Line Sex - Female (40),Insulin Start Day - 1 (19),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),2D Surface - Electrospun (13),Contractile Analysis Method - Traction Force Microscopy (9),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Seeding Confluency 3D (%) - 85 to 89 (12),2D Surface - Microparticle/fluid (3),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Contractile Analysis Method - Motion Tracking (93),Cell Line Sex - Both (118),Pharmacological Intervention - Isoproterenol (71),hiPSC-CM Media Supplement - Rare (5),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Biomaterials (16),3D Stromal Cell Source - hiPSC-MuralC (3),3D Stromal Cell Source - Human Fibroblast (38),Number of Cell Lines - 3 (29),Metabolic Analysis Method - Seahorse (35),Metabolic Analysis Method - Seahorse (35),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Nat Biomed Eng (5),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Stromal Cell Source - Cardiac Fibroblast (32),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),3D Platform - 3D printed (9),Wnt Inhibitor - DS-I-7 (9),3D Platform - Scaffold Free (43),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D Tissue Media - Iscove (5),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Journal - Circ Res (5),3D Stromal Cell Source - Rare (4),3D Stromal Cell Source - Stromal Cell (35),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Deduced Culture Strategy - 3D Only (157),Cell Line - iCell2 (8),Day of Insulin Addition - not 21 (14),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Metabolic Analysis Method - Genetic (3),3D Stromal Cell Source - Stromal Cell (35),Maturation Strategy - ECM (21),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Maturation Strategy - Elastomeric (33),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency 3D (%) - 90 to 94 (13),Insulin Start Day - 8 (15),Pharmacological Intervention - Isoproterenol (71),Journal - ACS Appl Mater Interfaces (4),Pharmacological Intervention - QT-Prolonging Drugs (36),Pharmacological Intervention - Cisapride (8),Metabolic Analysis Method - Seahorse (35),hiPSC-CM Media Supplement - Lipids (9),Pharmacological Intervention - E4031 (22),hiPSC-CM Purification Duration (days) - 6 days (10),Wnt Induction - BMP4 (74),Wnt Inhibitor Duration (days) - Rare (173),hiPSC Backbone Media - Embryonic Stem Cell (127),Pharmacological Intervention - Carbamylcholine (6),Publication Year - 2018 (45),hiPSC-CM Purification Duration (days) - 4 days (29),Contractile Analysis Method - Deflection (39),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),New Media for Maturation - DMEM (21),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Maturation Strategy - Cell Alignment (59),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),3D Tissue Media - MEM-α (60),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),3D Tissue Media - MEM-α (60),Disease Modelling - Arrhythmic (15),Contractile Analysis Method - Motion Tracking (93),hiPSC-CM Maturation Media - Rare (9),Number of Cell Lines - 3 (29),Seeding Confluency (%) - 80 to 84 (12),Seeding Confluency 3D (%) - 85 to 89 (12),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Nat Commun (13),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Insulin Start Day - 6 (20),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Cell Line - Rare (132),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),hiPSC Matrix Coating - Geltrex (33),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Electrophysiology Analysis Method - Microelectrode (31),Journal - Toxicological Sciences (4),Wnt Inhibitor - KY02111 (7),Journal - Toxicological Sciences (4),Cell Line - C25 (6),hiPSC-CM Purification Duration (days) - 5 days (6),hiPSC-CM Maturation Media - iCell Maintenance (83),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Disease Modelling - Genetic Disorders (18),Coating for Replating - Gelatin (43)
hiPSC-CM Maturation Media - DMEM (35),Deduced Culture Strategy - 2D Only (183),hiPSC Backbone Media - Conditioned (12),Wnt Inhibitor - IWP (112),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Metabolic Component - Fatty Acid (13),Disease Modelling - Dilated Cardiomyopathy (6),Journal - PLoS One (9),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Pharmacological Intervention - QT-Prolonging Drugs (36),2D Surface - Nanotopography (6),Sacromere or Cellular Alignment Analysis - Yes (72),3D Platform - Matrigel (33),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Seeding Confluency (%) - 95 to 100 (23),Journal - Biomaterials (16),3D Tissue Media - MEM-α (60),Seeding Confluency (%) - 70 to 79 (11),Electrophysiology Analysis Method - Patch Clamp (59),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Fatty Acid Metabolism Assessed - Yes (20),Metabolic Analysis Method - Seahorse (35),hiPSC-CM Maturation Media - iCell Maintenance (83),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),Cell Line Ancestry - Asian (28),Cell Line - iCell2 (8),Maturation Strategy - Electrical (39),Cell Line - BJ1 (7),Wnt Induction - BMP4 (74),Maturation Strategy - Other Cells (80),Calcium Handling Analysis Method - Visual (104),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Maturation Strategy - Tension (64),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),3D Tissue Media - MEM-α (60),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - Biosens Bioelectron (4),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),hiPSC-CM Purification Duration (days) - 6 days (10),hiPSC Backbone Media - Embryonic Stem Cell (127),Deduced Culture Strategy - 3D Only (157),3D Tissue Media - MEM-α (60),Journal - Stem Cell Reports (23),Journal - Nat Biomed Eng (5),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Journal - J Mol Cell Cardiol (4),Calcium Handling Analysis Method - Visual (104),Metabolic Analysis Method - Flux Rates (13),Sacromere or Cellular Alignment Analysis - Yes (72),3D Platform - Extracellular Scaffold (18),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Publication Year - 2016 (32),Coating for Replating - Vitronectin (3),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),hiPSC-CM Purification Duration (days) - 4 days (29),Insulin Start Day - 10 (6),3D Stromal Cell Source - Rare (4),Metabolic Component - Dexamethasone (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),3D Stromal Cell Source - Rare (4),Pharmacological Intervention - E4031 (22),Calcium Handling Analysis Method - Genetic (23),Disease Modelling - Genetic Disorders (18),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),hiPSC-CM Media Supplement - B27 (180),hiPSC Backbone Media - mTeSR (106),Cell Line - 201B6 (3),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Journal - Tissue Eng Part A (4),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Publication Year - 2022 (20),Pharmacological Intervention - Positive Inotropes (9),Cell Line Ancestry - Caucasian (41),Differentiation Purity Assessment - Visual Inspection (6),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Deduced Culture Strategy - 3D Only (157),Number of Cell Lines - >5 (9),Electron Imaging - Scanning (22),Electron Imaging - Scanning (22),Cell Line - WTC11 (30),3D Platform - Extracellular Scaffold (18),Electron Imaging - Scanning (22),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Contractile Analysis Method - Deflection (39),Publication Year - 2016 (32),Publication Year - 2016 (32),Publication Year - 2019 (57),hiPSC-CM Purification Duration (days) - 5 days (6),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),hiPSC-CM Media Supplement - Rare (5),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Insulin Start Day - 6 (20),hiPSC-CM Backbone Media - iCell Maintenance (86),hiPSC-CM Backbone Media - iCell Maintenance (86),Insulin Start Day - 11 (3),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - iCell (47),Seeding Confluency 2D (%) - 95 to 100 (6),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Seeding Confluency 2D (%) - 95 to 100 (6),Electrophysiology Analysis Method - Optical Mapping (39),Coating for Replating - Matrigel (65),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7)
Insulin Start Day - 6 (20),Cell Line - Cellapy (4),3D Stromal Cell Source - Human Fibroblast (38),Pharmacological Intervention - β1/β2-Adrenergic Agonists (Pure β-Agonists) (73),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Pharmacological Intervention - Carbamylcholine (6),Coating for Replating - Fibronectin (32),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Metabolic Component - Rare (4),Metabolic Component Category - Signaling Pathway Regulators (6),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D Platform - Extracellular Scaffold (18),Maturation Strategy - Elastomeric (33),3D Stromal Cell Source - Human Fibroblast (38),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Maturation Strategy - Other Cells (80),3D Tissue Media - DMEM (53),hiPSC-CM Backbone Media - RPMI-1640 (167),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Calcium Handling Analysis Method - Rare (4),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Number of Cell Lines - 4 (11),Sacromere or Cellular Alignment Analysis - Yes (72),Electron Imaging - Transmission (62),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),3D Tissue Media - Commercial Kit (21),Wnt Inhibitor Duration (days) - >6 days (12),Publication Year - 2017 (43),hiPSC-CM Media Supplement - Ascorbic Acid (41),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Electron Imaging - Transmission (62),hiPSC-CM Media Supplement - bFGF (3),Seeding Confluency 3D (%) - 85 to 89 (12),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),3D Tissue Media - RPMI-1640 (72),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Endothelial Cell Source - hiPSC-EndothelialC (16),3D Platform - Collagen (38),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),hiPSC-CM Media Supplement - FBS (16),Maturation Strategy - Electrical (39),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Cell Line - PGP1 (11),Deduced Culture Strategy - 3D Only (157),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Coating for Replating - Laminin (5),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Contractile Analysis Method - Rare (7),Journal - ACS Appl Mater Interfaces (4),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Journal - J Mol Cell Card (6),Cell Line - PGP1 (11),Pharmacological Intervention - Adrenaline (83),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Pharmacological Intervention - QT-Prolonging Drugs (36),Maturation Strategy - Electrical (39),Differentiation Purity Assessment - IHC a-actinin (8),Insulin Start Day - 8 (15),hiPSC-CM Media Supplement - GlutaMax (8),Cell Line - iCell2 (8),Wnt Inhibitor - KY02111 (7),Wnt Induction - BMP4 (74),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Metabolic Component - Galactose (4),Wnt Inhibitor - IWP (112),Wnt Inhibitor Duration (days) - Rare (173),Insulin Start Day - 5 (14),Wnt Induction - bFGF (45),Day of Insulin Addition - not 21 (14),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Maturation Strategy - ECM (21),hiPSC Backbone Media - mTeSR (106),Publication Year - 2015 (19),Purification Protocol - Glucose and Lactate (85),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Purification Duration (days) - 5 days (6),Publication Year - 2016 (32),Publication Year - 2016 (32),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Calcium Handling Analysis Method - Visual (104),Cell Line Ancestry - Caucasian (41),hiPSC-CM Backbone Media - iCell Maintenance (86),3D Stromal Cell Source - Human Fibroblast (38),Electron Imaging - Transmission (62),3D Platform - Polyethylene Glycol (8),Insulin Withdrawal Duration (days) - 8 days (3),3D Tissue Media - Commercial Kit (21),Journal - Nat Commun (13),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Disease Modelling - Ischemic Infarction (9),hiPSC-CM Purification Duration (days) - 5 days (6),Maturation Strategy - ECM (21),Coating for Replating - Gelatin (43),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Calcium Handling Analysis Method - Visual (104),3D Tissue Media - Iscove (5),Journal - Cell Rep (6),Number of Cell Lines - >5 (9),2D Surface - Nanotopography (6),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Wnt Inhibitor - BMP4 (7),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Cell Line - Cor.4U (16),Insulin Start Day - After 11 (7),hiPSC-CM Maturation Media - iCell Maintenance (83)
Cell Line - Cellapy (4),Wnt Induction Duration (days) - 3 days (38),Insulin Start Day - 11 (3),Number of Cell Lines - 2 (50),hiPSC-CM Media Supplement - Rare (5),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),3D Platform - Extracellular Scaffold (18),hiPSC Backbone Media - mTeSR (106),Cell Line Ancestry - Caucasian (41),Insulin Start Day - 3 (5),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),Seeding Confluency (%) - Rare (43),Cell Line - C25 (6),Seeding Confluency 3D (%) - 95 to 100 (13),hiPSC-CM Purification Duration (days) - 4 days (29),Pharmacological Intervention - T3 (3),hiPSC-CM Purification Duration (days) - 3 days (13),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),Seeding Confluency 3D (%) - 90 to 94 (13),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),hiPSC-CM Maturation Media - RPMI-1640 (153),Journal - J Biomed Mater Res A (3),Insulin Start Day - 6 (20),Maturation Strategy - Tension (64),Maturation Strategy - Cell Alignment (59),Contractile Analysis Method - Deflection (39),Journal - J Biomed Mater Res A (3),3D Stromal Cell Source - hiPSC-SmoothMC (3),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),3D Tissue Media - iCell Maintenance (12),3D Tissue Media - iCell Maintenance (12),Wnt Inhibitor - DS-I-7 (9),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Pharmacological Intervention - Doxorubicin (17),Seeding Confluency 3D (%) - 85 to 89 (12),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Contractile Stress (mN/mm2) Quantiles - Q3 (>0.51 and ≤1.9) (9),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),hiPSC Backbone Media - mTeSR (106),Pharmacological Intervention - Phenylephrine (3),Cell Line Sex - Female (40),hiPSC-CM Media Supplement - Selenium (7),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),hiPSC Matrix Coating - MEF feeder cells (8),Wnt Induction - Activin A (80),Day of Insulin Addition - not 24 (9),Wnt Inhibitor - Rare (3),Cell Line Ancestry - Asian (28),3D Platform - Scaffold Free (43),Pharmacological Intervention - Adrenaline (83),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),Metabolic Component Category - Kinase Inhibitors (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Journal - Biomaterials (16),Calcium Handling Analysis Method - Rare (4),Journal - Stem Cells (11),Cell Line Ancestry - Caucasian (41),Disease Modelling - Specialised (3),Calcium Handling Analysis Method - Visual (104),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Insulin Start Day - 8 (15),3D Stromal Cell Source - Cardiac Fibroblast (32),hiPSC Backbone Media - Rare (19),Calcium Handling Analysis Method - Visual (104),Wnt Induction - BMP4 (74),hiPSC-CM Media Supplement - B27 (180),Wnt Induction - bFGF (45),Wnt Induction - BMP4 (74),Day of Insulin Addition - not 22 (12),hiPSC Matrix Coating - Geltrex (33),Electrophysiology Analysis Method - Patch Clamp (59),Metabolic Component - Ascorbic Acid (3),Publication Year - 2024 (7),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),3D Platform - Matrigel (33),Contractile Analysis Method - Deflection (39),3D Stromal Cell Source - Human Fibroblast (38),hiPSC Backbone Media - Essential 8 (82),Maturation Strategy - Electrical (39),Journal - Nat Commun (13),hiPSC-CM Backbone Media - iCell Maintenance (86),Calcium Handling Analysis Method - Visual (104),Journal - Sci Rep (24),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),3D Tissue Media - Commercial Kit (21),hiPSC-CM Purification Duration (days) - 8 days (4),Cell Coculture - Endothelial Cell (35),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Sci Rep (24),Coating for Replating - Matrigel (65),Coating for Replating - Matrigel (65),Coating for Replating - Gelatin (43),Publication Year - 2017 (43),Publication Year - 2017 (43),3D Tissue Media - Commercial Kit (21),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),3D Platform - Nanotechnology (3),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Calcium Handling Analysis Method - Genetic (23),Wnt Inhibitor - bFGF (8),Journal - Acta Biomater (10),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Differentiation Purity Assessment - IHC a-actinin (8)
hiPSC Backbone Media - Rare (19),Journal - Rare (104),hiPSC-CM Purification Duration (days) - <3 days (31),Pharmacological Intervention - Isoproterenol (71),Cell Line - BJ RiPS (4),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Insulin Start Day - 8 (15),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),hiPSC-CM Media Supplement - GlutaMax (8),Journal - Acta Biomater (10),Contractile Analysis Method - Deflection (39),hiPSC-CM Maturation Media - Commercial Kit (27),hiPSC Backbone Media - Rare (19),Journal - Cell Stem Cell (6),2D Surface - Micropatterned (27),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),3D Stromal Cell Source - Dermal Fibroblast (7),Wnt Inhibitor Duration (days) - 4 days (19),3D Stromal Cell Source - Cardiac Fibroblast (32),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Journal - Rare (104),Wnt Inhibitor - Wnt-C59 (30),Journal - Stem Cell Res (8),Insulin Start Day - 1 (19),Electron Imaging - Scanning (22),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),hiPSC Matrix Coating - Geltrex (33),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),Differentiation Purity Assessment - IHC cTnT (7),3D Platform - Scaffold Free (43),Number of Cell Lines - >5 (9),Insulin Start Day - 4 (11),hiPSC Backbone Media - Conditioned (12),Gene Analysis Method - RNA (169),Disease Modelling - Genetic Disorders (18),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Differentiation Purity (%) Quantiles - Q1 (>95 and ≤99) (22),hiPSC-CM Maturation Media - Commercial Kit (27),,3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),3D Platform - Scaffold Free (43),3D Stromal Cell Source - hiPSC-MuralC (3),3D Platform - 3D printed (9),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Coating for Replating - Fibronectin (32),Deduced Culture Strategy - 2D Only (183),2D Surface - Micropatterned (27),Electrophysiology Analysis Method - Patch Clamp (59),Cell Line - 201B7 (9),3D Platform - Matrigel (33),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),3D Stromal Cell Source - Human Fibroblast (38),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),Metabolic Component Category - Kinase Inhibitors (3),Wnt Inhibitor - IWP (112),Journal - Acta Biomater (10),Publication Year - 2015 (19),Journal - Tissue Eng Part A (4),Seeding Confluency (%) - 85 to 89 (43),Insulin Start Day - 7 (85),3D Stromal Cell Source - Rare (4),Journal - Circulation (11),Pharmacological Intervention - Adrenaline (83),New Media for Maturation - Commercial Kit (5),hiPSC-CM Media Supplement - Mercaptoethanol (10),3D Stromal Cell Source - hiPSC-SmoothMC (3),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),hiPSC-CM Media Supplement - Polyvinylalchohol (6),2D Surface - Microelectrode Array (9),Cell Line Ancestry - Asian (28),Cell Line - BJ RiPS (4),Seeding Confluency 3D (%) - 95 to 100 (13),hiPSC Backbone Media - mTeSR (106),hiPSC-CM Purification Duration (days) Quantiles - Q2 (>1 and ≤4) (61),Insulin Start Day - 4 (11),Cell Line - 201B6 (3),Insulin Withdrawal Duration (days) - 4 days (18),Journal - Am J Physiol Heart Circ Physiol (4),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Metabolic Component - Fatty Acid (13),3D Platform - Collagen (38),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),3D Tissue Media - Iscove (5),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Backbone Media - Cor.4U Complete (6),hiPSC-CM Backbone Media - iCell Maintenance (86),Contractile Analysis Method - Motion Tracking (93),Cell Line Ancestry - Asian (28),Seeding Confluency 3D (%) - 90 to 94 (13),Wnt Inhibitor Duration (days) - 4 days (19),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Publication Year - Late-2010s (196),Journal - Nat Commun (13),2D Surface - ECM-coated (115),Coating for Replating - Gelatin (43),3D Tissue Media - Rare (13),3D Tissue Media - Rare (13),Coating for Replating - Geltrex (10),Number of Cell Lines - 4 (11),Number of Cell Lines - 2 (50),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Publication Year - 2017 (43),Coating for Replating - Rare (6),Journal - Cell Rep (6),Number of Cell Lines - 3 (29),Differentiation Purity Assessment - IHC cTnT (7),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),hiPSC-CM Media Supplement - GlutaMax (8),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),Maturation Strategy - Metabolic (33),Maturation Strategy - Cell Alignment (59)
Seeding Confluency 3D (%) - 85 to 89 (12),Seeding Confluency 2D (%) - 80 to 84 (5),Wnt Inhibitor - IWP (112),Maturation Strategy - Tension (64),3D Tissue Media - RPMI-1640 (72),Publication Year - Late-2010s (196),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),2D Surface - Hydrogel (17),Journal - Biomater Sci (7),Wnt Inhibitor Duration (days) - 3 days (17),hiPSC-CM Media Supplement - VEGF (4),Contractile Analysis Method - Traction Force Microscopy (9),Metabolic Component - Lactate (4),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - Tension (64),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Visual (104),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),Cell Line - Cor.4U (16),New Media for Maturation - F12 (7),Coating for Replating - Vitronectin (3),hiPSC-CM Media Supplement - Ascorbic Acid (41),2D Surface - Electrospun (13),Cell Line Ancestry - Asian (28),Electrophysiology Analysis Method - Microelectrode (31),Wnt Inhibitor Duration (days) - 5 days (6),hiPSC Backbone Media - mTeSR (106),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Cell Line - Rare (132),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Journal - Nano Lett (3),Wnt Induction Duration (days) - 4 days (15),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),Journal - Nat Biomed Eng (5),Maturation Strategy - Cell Alignment (59),3D Stromal Cell Source - Cardiac Fibroblast (32),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),,hiPSC Backbone Media - Conditioned (12),Maturation Strategy - Other Cells (80),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Wnt Inhibitor Duration (days) - >6 days (12),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),hiPSC-CM Maturation Media - Commercial Kit (27),Journal - Nano Lett (3),Journal - J Mol Cell Cardiol (4),hiPSC Matrix Coating - MEF feeder cells (8),Cell Line - BJ RiPS (4),Insulin Start Day - 6 (20),3D Platform - Extracellular Scaffold (18),Cell Line Sex - Female (40),Wnt Induction Duration (days) Quantiles - Q2 (>1 and ≤2) (75),3D Stromal Cell Source - hiPSC-SmoothMC (3),3D Tissue Media - Commercial Kit (21),Journal - J Mol Cell Cardiol (4),Publication Year - 2018 (45),Wnt Induction - StemCell Diff Kit (4),Journal - Am J Physiol Heart Circ Physiol (4),Seeding Confluency 3D (%) - 80 to 84 (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Differentiation Purity Assessment - Rare (3),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Maturation Strategy - Mechanical (36),Pharmacological Intervention - Carbenoxolone (4),Insulin Start Day - 6 (20),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Metabolic Analysis Method - Seahorse (35),Cell Line - BJ1 (7),Insulin Start Day - 9 (10),Wnt Induction - Wnt3a (3),Wnt Induction - Wnt3a (3),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Rare (104),hiPSC Backbone Media - DMEM (10),hiPSC-CM Maturation Media - iCell Maintenance (83),3D Platform - 3D printed (9),3D Stromal Cell Source - Cardiac Fibroblast (32),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Electron Imaging - Scanning (22),Maturation Strategy - ECM (21),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Publication Year - 2017 (43),Publication Year - 2017 (43),New Media for Maturation - Rare (4),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Gene Analysis Method - RNA (169),Publication Year - 2020 (51),Maturation Strategy - Other Cells (80),3D Platform - Polyethylene Glycol (8),Wnt Inhibitor - DS-I-7 (9),Cell Coculture - Endothelial Cell (35),2D Surface - ECM-coated (115),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Contractile Analysis Method - Traction Force Microscopy (9),2D Surface - Microelectrode Array (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Journal - Cell Rep (6),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Maturation Strategy - ECM (21),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Wnt Inhibitor - Wnt-C59 (30),Gene Analysis Method - RNA (169),hiPSC-CM Backbone Media - iCell Maintenance (86),Publication Year - 2021 (43),hiPSC-CM Purification Duration (days) - 5 days (6),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6)
Wnt Induction - Rare (4),2D Surface - Micropatterned (27),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Pharmacological Intervention - Class IV Antiarrhythmics (Ca2+ Channel Blockers - AV Nodal Block) (30),Cell Line Sex - Male (64),Insulin Start Day - 1 (19),Pharmacological Intervention - Propranolol (5),Sacromere or Cellular Alignment Analysis - Yes (72),3D Tissue Media - Growth Factor (12),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC-CM Media Supplement - L-glutamine (19),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Maturation Strategy - Electrical (39),Seeding Confluency 2D (%) - 70 to 79 (6),Publication Year - 2019 (57),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),hiPSC Matrix Coating - EBs (18),Pharmacological Intervention - Carbenoxolone (4),3D Platform - Extracellular Scaffold (18),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Metabolic Analysis Method - Genetic (3),Gene Analysis Method - Rare (5),3D Tissue Media - High-glucose DMEM (9),Metabolic Component - Rare (4),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Journal - Biomaterials (16),Metabolic Component Category - Fatty Acids and Lipids (21),3D Platform - Extracellular Scaffold (18),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Metabolic Component Category - Signaling Pathway Regulators (6),Seeding Confluency 2D (%) - 85 to 89 (26),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Lab Chip (4),Pharmacological Intervention - T3 (3),Calcium Handling Analysis Method - Visual (104),2D Surface - Hydrogel (17),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),Cell Line - WTC11 (30),,3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Maturation Strategy - Tension (64),,3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),Pharmacological Intervention - Carbenoxolone (4),Coating for Replating - Gelatin (43),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Coating for Replating - Laminin (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Insulin Start Day - 6 (20),Seeding Confluency 3D (%) - Rare (26),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Contractile Analysis Method - Traction Force Microscopy (9),Journal - Nat Commun (13),2D Surface - Micropatterned (27),Publication Year - 2024 (7),Journal - Tissue Eng Part A (4),Seeding Confluency 2D (%) - 90 to 94 (12),hiPSC Backbone Media - Embryonic Stem Cell (127),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Journal - Stem Cell Reports (23),3D Platform - Nanotechnology (3),Day of Insulin Addition - not 16 (15),Pharmacological Intervention - Cisapride (8),Seeding Confluency (%) - 85 to 89 (43),Electrophysiology Analysis Method - Microelectrode (31),Cell Line - ATCC (5),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),Pharmacological Intervention - Lidocaine (7),Pharmacological Intervention - Carbamylcholine (6),hiPSC-CM Media Supplement - Ascorbic Acid (41),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Cell Line - BJ1 (7),3D Stromal Cell Source - hiPSC-MuralC (3),Disease Modelling - Hypertrophic Cardiomyopathy (6),Day of Insulin Addition - not 24 (9),Journal - Circulation (11),Journal - Sci Transl Med (3),Insulin Start Day - After 11 (7),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Coating for Replating - Fibronectin (32),3D Tissue Media - Growth Factor (12),Journal - Sci Rep (24),3D Platform - Nanotechnology (3),Electrophysiology Analysis Method - Optical Mapping (39),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Electron Imaging - Scanning (22),Electrophysiology Analysis Method - Patch Clamp (59),2D Surface - Electrospun (13),Disease Modelling - Arrhythmic (15),2D Surface - ECM-coated (115),Insulin Withdrawal Duration (days) - 8 days (3),Coating for Replating - Rare (6),Cell Line - iCell2 (8),Electrophysiology Analysis Method - Optical Mapping (39),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Electrophysiology Analysis Method - Patch Clamp (59),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),hiPSC-CM Purification Duration (days) - <3 days (31),3D Platform - Matrigel (33),Coating for Replating - Rare (6),Number of Cell Lines - >5 (9),Coating for Replating - Gelatin (43),Number of Cell Lines - 2 (50),Journal - Cell Stem Cell (6),2D Surface - Electrospun (13),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Maturation Strategy - Electrical (39),hiPSC Backbone Media - Rare (19),Journal - Rare (104)
Metabolic Component - Palmitic Acid (11),2D Surface - Microparticle/fluid (3),Pharmacological Intervention - T3 (3),3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Publication Year - 2015 (19),Insulin Withdrawal Duration (days) - 3 days (6),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),hiPSC-CM Media Supplement - FBS (16),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Number of Cell Lines - 3 (29),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),3D Stromal Cell Source - Rare (4),Metabolic Component - B27 (3),Publication Year - 2022 (20),Publication Year - 2019 (57),3D Stromal Cell Source - hiPSC-CardiacF (8),Seeding Confluency 3D (%) - 85 to 89 (12),Cell Line Sex - Female (40),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Number of Cell Lines - 4 (11),Day of Insulin Addition - not 22 (12),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Publication Year - 2014 (3),Insulin Start Day - 9 (10),Differentiation Purity Assessment - Visual Inspection (6),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Coating for Replating - Geltrex (10),Journal - PLoS One (9),Metabolic Component - Fatty Acid (13),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),Seeding Confluency (%) - Rare (43),Pharmacological Intervention - ACE Inhibitors (RAAS Modulators) (3),Disease Modelling - Genetic Disorders (18),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Maturation Strategy - Other Cells (80),,3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),3D Platform - Collagen (38),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),,Disease Modelling - Fibrotic (4),3D Tissue Media - Growth Factor (12),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Pharmacological Intervention - Adrenaline (83),Journal - Circulation (11),Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),Maturation Strategy - Tension (64),Pharmacological Intervention - Rare (3),Contractile Analysis Method - Deflection (39),Wnt Inhibitor - XAV939 (24),Journal - ACS Biomater Sci Eng (3),Insulin Start Day - 7 (85),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Cell Line - DF19-9-11T.H (16),Journal - Nat Biomed Eng (5),Disease Modelling - Hypertrophic Cardiomyopathy (6),Number of Cell Lines - 3 (29),Cell Line - IMR90 (19),Wnt Induction Duration (days) - 3 days (38),Day of Insulin Addition - not 14 (15),Journal - Stem Cell Res (8),Wnt Inhibitor - IWR (56),3D Tissue Media - Rare (13),Coating for Replating - Laminin (5),Number of Cell Lines - 3 (29),Wnt Inhibitor Duration (days) - 4 days (19),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Publication Year - Late-2010s (196),3D Platform - Scaffold Free (43),Seeding Confluency 3D (%) - 85 to 89 (12),Cell Line Ancestry - Caucasian (41),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),hiPSC-CM Media Supplement - Polyvinylalchohol (6),Pharmacological Intervention - Cardiotoxic Agents (3),Journal - Biosens Bioelectron (4),Pharmacological Intervention - Lidocaine (7),Contractile Analysis Method - Motion Tracking (93),Deduced Culture Strategy - 2D Only (183),3D Platform - 3D printed (9),New Media for Maturation - Rare (4),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Journal - Sci Rep (24),hiPSC Matrix Coating - Geltrex (33),Journal - Toxicological Sciences (4),Coating for Replating - Gelatin (43),Number of Cell Lines - 3 (29),Cell Line - iCell2 (8),Number of Cell Lines - 3 (29),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Cell Coculture - Endothelial Cell (35),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Journal - Cell Stem Cell (6),3D Tissue Media - Commercial Kit (21),Cell Line - iCell (47),Journal - Toxicological Sciences (4),Maturation Strategy - Electrical (39),Cell Line - Cor.4U (16),Wnt Inhibitor - DS-I-7 (9),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Coating for Replating - Rare (6),Maturation Strategy - Electrical (39),Electrophysiology Analysis Method - Optical Mapping (39),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Insulin Start Day - 9 (10),Maturation Strategy - Elastomeric (33),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),Seeding Confluency 3D (%) - 85 to 89 (12)
Coating for Replating - Geltrex (10),Metabolic Component - Insulin-Transferrin-Selenium (3),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),3D Tissue Media - High-glucose DMEM (9),Electron Imaging - Transmission (62),hiPSC-CM Purification Duration (days) Quantiles - Q1 (>4 and ≤20) (31),Contractile Analysis Method - Deflection (39),Coating for Replating - Matrigel (65),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Metabolic Component Category - Kinase Inhibitors (3),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),,Metabolic Component Category - Kinase Inhibitors (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Pharmacological Intervention - Doxorubicin (17),Pharmacological Intervention - Cisapride (8),Maturation Strategy - Tension (64),Pharmacological Intervention - Verapamil (27),Disease Modelling - Dilated Cardiomyopathy (6),Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Journal - Stem Cells Transl Med (3),Journal - Lab Chip (4),New Media for Maturation - Commercial Kit (5),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Cell Line - DF19-9-11T.H (16),3D Tissue Media - RPMI-1640 (72),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),3D Tissue Media - Rare (13),Cell Line - iCell2 (8),Pharmacological Intervention - Carbenoxolone (4),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Calcium Handling Analysis Method - Genetic (23),,Electron Imaging - Transmission (62),Contractile Analysis Method - Motion Tracking (93),Journal - Rare (104),,3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Endothelial Cell Source - Rare (3),,3D Endothelial Cell Source - hiPSC-EndothelialC (16),hiPSC Backbone Media - Conditioned (12),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Journal - Stem Cells Int (3),Cell Line - IMR90 (19),hiPSC-CM Media Supplement - Polyvinylalchohol (6),3D Platform - Extracellular Scaffold (18),Publication Year - Post 2020 (122),Publication Year - 2021 (43),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Seeding Confluency 2D (%) - 85 to 89 (26),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Cell Line - 253G1 (10),Cell Line - IMR90 (19),3D Tissue Media - High-glucose DMEM (9),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),3D Estimated Tissue Size (mm2) Quantiles - Q3 (>2 and ≤9.12) (21),Seeding Confluency 2D (%) - 70 to 79 (6),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Calcium Handling Analysis Method - Visual (104),Journal - Stem Cells Int (3),Journal - J Mol Cell Cardiol (4),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),hiPSC-CM Purification Duration (days) - <3 days (31),Journal - Sci Transl Med (3),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),hiPSC-CM Media Supplement - 1-thioglycerol (14),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),hiPSC-CM Purification Duration (days) - 4 days (29),hiPSC Backbone Media - DMEM (10),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Journal - Nat Biomed Eng (5),3D Platform - Matrigel (33),hiPSC-CM Backbone Media - Rare (10),Pharmacological Intervention - Mixed α/β-Adrenergic Agonists (12),hiPSC-CM Maturation Media - RPMI-1640 (153),2D Surface - Micropatterned (27),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Cell Line - iCell2 (8),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Genetic (23),Publication Year - 2017 (43),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Journal - Sci Rep (24),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Cell Line - iCell (47),Publication Year - 2021 (43),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Platform - Scaffold Free (43),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),hiPSC-CM Media Supplement - Lipid Mix (5),3D Platform - Extracellular Scaffold (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Disease Modelling - Genetic Disorders (18),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),2D Surface - ECM-coated (115),Number of Cell Lines - 4 (11),hiPSC-CM Maturation Media - iCell Maintenance (83),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Wnt Inhibitor - Others (9),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Coating for Replating - Gelatin (43),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),2D Surface - Microelectrode Array (9)
Publication Year - 2019 (57),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),hiPSC-CM Purification Duration (days) - 7 days (6),3D Stromal Cell Source - Cardiac Fibroblast (32),Journal - Circ Res (5),Journal - Stem Cell Res Ther (3),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),hiPSC-CM Purification Duration (days) - 3 days (13),Calcium Handling Analysis Method - Visual (104),Pharmacological Intervention - Metoprolol (5),Seeding Confluency 2D (%) - Rare (13),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Electrophysiology Analysis Method - Patch Clamp (59),,,3D Tissue Media - RPMI-1640 (72),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Platform - Polyethylene Glycol (8),Publication Year - 2021 (43),Journal - Stem Cell Res (8),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Media Supplement - B27 (180),Cell Line - Gibco episomal (10),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Cell Line - WTC11 (30),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),3D Stromal Cell Source - hiPSC-CardiacF (8),Journal - J Mol Cell Cardiol (4),Publication Year - 2022 (20),Electrophysiology Analysis Method - Microelectrode (31),Metabolic Component Category - Sugars and Carbohydrates (9),Wnt Induction - Wnt3a (3),Disease Modelling - Genetic Disorders (18),Publication Year - 2014 (3),,Pharmacological Intervention - T3 (3),hiPSC Backbone Media - StemFit (5),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),,Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Insulin Start Day - 9 (10),,3D Stromal Cell Source - Dermal Fibroblast (7),Coating for Replating - Geltrex (10),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Cell Line - DF19-9-11T.H (16),Disease Modelling - Arrhythmic (15),hiPSC-CM Maturation Media - F12 (10),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Gene Analysis Method - Rare (5),Maturation Strategy - Other Cells (80),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),3D Platform - 3D printed (9),Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),Wnt Induction Duration (days) Quantiles - Q3 (>1 and ≤1) (186),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Metabolic Component Category - Hormonal Stimulation (14),Journal - Nat Biomed Eng (5),Cell Line - WTC11 (30),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Pharmacological Intervention - Carbenoxolone (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Journal - Nano Lett (3),Insulin Withdrawal Duration (days) - 8 days (3),Metabolic Component - Palmitic Acid (11),Seeding Confluency 3D (%) - 80 to 84 (5),hiPSC-CM Media Supplement - Selenium (7),Seeding Confluency (%) - 70 to 79 (11),Cell Line Sex - Both (118),Seeding Confluency 2D (%) - 70 to 79 (6),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),hiPSC-CM Media Supplement - Mercaptoethanol (10),Calcium Handling Analysis Method - Genetic (23),hiPSC-CM Media Supplement - Lipids (9),Wnt Induction Duration (days) - 4 days (15),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Number of Cell Lines - 2 (50),Insulin Start Day - 9 (10),Metabolic Component - KOSR (3),3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Journal - Toxicological Sciences (4),3D Stromal Cell Source - Cardiac Fibroblast (32),Journal - Biomaterials (16),Number of Cell Lines - 3 (29),hiPSC-CM Maturation Media - iCell Maintenance (83),Journal - Sci Rep (24),Electrophysiology Analysis Method - Microelectrode (31),hiPSC-CM Media Supplement - L-glutamine (19),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Publication Year - 2020 (51),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Insulin Start Day - 4 (11),Journal - Rare (104),3D Platform - Extracellular Scaffold (18),Number of Cell Lines - 4 (11),3D Tissue Media - Rare (13),Coating for Replating - Gelatin (43),3D Stromal Cell Source - Cardiac Fibroblast (32),3D Platform - Extracellular Scaffold (18),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Disease Modelling - Arrhythmic (15),hiPSC-CM Media Supplement - Albumin (28),Differentiation Purity Assessment - IHC a-actinin (8),Cell Line - DF19-9-11T.H (16),Wnt Inhibitor - Others (9),Maturation Strategy - ECM (21),Seeding Confluency 2D (%) - 85 to 89 (26),hiPSC-CM Backbone Media - iCell Maintenance (86)
Metabolic Component Category - Kinase Inhibitors (3),hiPSC-CM Media Supplement - Rare (5),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Pharmacological Intervention - Adrenaline (83),Journal - Sci Transl Med (3),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Cell Line - Cor.4U (16),Seeding Confluency 2D (%) - 70 to 79 (6),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Cell Line - iCell (47),Number of Cell Lines - >5 (9),Maturation Strategy - Elastomeric (33),hiPSC-CM Media Supplement - Lipids (9),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),,,Maturation Strategy - Elastomeric (33),Calcium Handling Analysis Method - Visual (104),3D Platform - Extracellular Scaffold (18),3D Estimated Cell Density (mil cells/mL) Quantiles - Q3 (>5 and ≤10) (30),Pharmacological Intervention - Phenylephrine (3),Cell Line - Gibco episomal (10),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Wnt Inhibitor Duration (days) - 5 days (6),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Cell Line - IMR90 (19),3D Stromal Cell Source - Dermal Fibroblast (7),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),Pharmacological Intervention - Carbenoxolone (4),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Journal - Sci Transl Med (3),Wnt Inhibitor - KY02111 (7),Journal - Stem Cells Int (3),,,Metabolic Component - IGF-1 (3),Publication Year - 2021 (43),hiPSC-CM Media Supplement - VEGF (4),,3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),3D Stromal Cell Source - hiPSC-SmoothMC (3),,,Journal - Nano Lett (3),Day of Insulin Addition - not 21 (14),Publication Year - 2016 (32),3D Stromal Cell Source - Rare (4),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),3D SC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤10) (29),Day of Insulin Addition - not 12 (11),Insulin Start Day - 11 (3),3D Stromal Cell Source - Mesenchymal Stem Cell (12),Seeding Confluency 2D (%) - 90 to 94 (12),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Journal - PLoS One (9),Journal - J Mol Cell Card (6),Seeding Confluency 2D (%) - 95 to 100 (6),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Calcium Handling Analysis Method - Visual (104),Insulin Start Day - After 11 (7),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Publication Year - 2015 (19),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),2D Surface - Micropatterned (27),Maturation Strategy - ECM (21),Calcium Handling Analysis Method - Rare (4),Electrophysiology Analysis Method - Microelectrode (31),Wnt Induction - bFGF (45),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),3D Tissue Media - Growth Factor (12),Cell Line - C25 (6),Insulin Withdrawal Duration (days) - 4 days (18),hiPSC Backbone Media - Conditioned (12),Seeding Confluency 3D (%) - Rare (26),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),hiPSC-CM Purification Duration (days) - 4 days (29),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Insulin Start Day - 9 (10),Coating for Replating - Fibronectin (32),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),hiPSC Backbone Media - Conditioned (12),Journal - Lab Chip (4),3D Platform - Gelatin (6),3D Stromal Cell Source - Human Fibroblast (38),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Cell Line - Cor.4U (16),Number of Cell Lines - >5 (9),Coating for Replating - Gelatin (43),Journal - Cell Rep (6),Cell Line - 253G1 (10),Cell Line - 253G1 (10),Insulin Start Day - 0 (7),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),3D Stromal Cell Source - Cardiac Fibroblast (32),Electron Imaging - Scanning (22),hiPSC-CM Maturation Media - Cor.4U Complete (6),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Publication Year - 2019 (57),Electrophysiology Analysis Method - Patch Clamp (59),Sacromere or Cellular Alignment Analysis - Yes (72),hiPSC-CM Backbone Media - StemPro-34 (14),3D Tissue Media - Iscove (5),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),Insulin Withdrawal Duration (days) - 6 days (3),Publication Year - 2016 (32),Purification Protocol - Cell Sorting (7),3D Platform - Nanotechnology (3)
Insulin Withdrawal Duration (days) - 6 days (3),2D Surface - Nanotopography (6),Cell Coculture - Cardiomyocyte (157),hiPSC Backbone Media - Embryonic Stem Cell (127),Wnt Inhibitor - Wnt-C59 (30),3D Platform - Matrigel (33),Metabolic Analysis Method - Genetic (3),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),2D Surface - ECM-coated (115),Journal - Front Cell Dev Biol (3),hiPSC-CM Maturation Media - RPMI-1640 (153),Cell Line - BJ1 (7),3D EC Ratio (CM-EC-SC) Quantiles - Q1 (>0 and ≤91) (31),,,3D Stromal Cell Source - hiPSC-CardiacF (8),Cell Line - 201B7 (9),Maturation Strategy - ECM (21),Maturation Strategy - ECM (21),Publication Year - 2024 (7),Seeding Confluency 2D (%) - 90 to 94 (12),Seeding Confluency 2D (%) - 90 to 94 (12),Contractile Analysis Method - Force Transducer (27),Day of Insulin Addition - not 22 (12),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Cell Coculture - Endothelial Cell (35),Differentiation Purity Assessment - Flow Cytometry cTnT+ (135),2D Surface - Decellularized ECM (3),Contraction Upstroke Velocity (um/s) Quantiles - Q3 (>10 and ≤31.5) (7),Publication Year - 2016 (32),Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),,,Pharmacological Intervention - Phenylephrine (3),Pharmacological Intervention - Traditional Chemotherapy Agents (18),3D CM Ratio (CM-EC-SC) Quantiles - Q3 (>9 and ≤75) (48),,3D Stromal Cell Source - Mesenchymal Stem Cell (12),3D Platform - Matrigel (33),3D Stromal Cell Source - hiPSC-CardiacF (8),,,Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Journal - Acta Biomater (10),T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),Journal - Stem Cells (11),Maturation Strategy - ECM (21),Journal - Circulation (11),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Number of Cell Lines - 4 (11),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),Disease Modelling - Rare (4),Insulin Withdrawal Duration (days) - 8 days (3),Calcium Handling Analysis Method - Rare (4),Metabolic Component Category - Kinase Inhibitors (3),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Publication Year - 2020 (51),Journal - Stem Cell Res Ther (3),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Day of Insulin Addition - not 10 (4),hiPSC-CM Media Supplement - Lipids (9),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),2D Surface - Electrospun (13),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),Publication Year - 2022 (20),hiPSC-CM Media Supplement - GlutaMax (8),3D Stromal Cell Source - hiPSC-MuralC (3),,TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),hiPSC-CM Backbone Media - Cor.4U Complete (6),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Journal - Cell Stem Cell (6),Wnt Inhibitor Duration (days) - Rare (173),Contractile Analysis Method - Deflection (39),hiPSC Matrix Coating - Geltrex (33),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),3D Tissue Media - Growth Factor (12),Publication Year - 2016 (32),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Backbone Media - Rare (10),hiPSC-CM Maturation Media - Rare (9),hiPSC-CM Backbone Media - iCell Maintenance (86),3D Platform - Extracellular Scaffold (18),Disease Modelling - Fibrotic (4),3D Tissue Media - Commercial Kit (21),Wnt Inhibitor - VEGF (3),Coating for Replating - Gelatin (43),2D Surface - ECM-coated (115),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Publication Year - Late-2010s (196),hiPSC-CM Maturation Media - Cor.4U Complete (6),hiPSC-CM Backbone Media - Cor.4U Complete (6),Cell Line - iCell2 (8),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Disease Modelling - Fibrotic (4),Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),2D Surface - ECM-coated (115),Disease Modelling - Hypertrophic Cardiomyopathy (6),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Insulin Start Day - 8 (15),Day of Insulin Addition - not 11 (5),Seeding Confluency 3D (%) - 90 to 94 (13),Journal - Circ Res (5),3D Tissue Media - iCell Maintenance (12)
Pharmacological Intervention - Caffeine (4),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Publication Year - 2014 (3),Electrophysiology Analysis Method - Optical Mapping (39),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Journal - Stem Cells (11),3D Tissue Media - Rare (13),Wnt Inhibitor - IWR (56),Journal - Biomaterials (16),Coating for Replating - Laminin (5),2D Surface - Hydrogel (17),Publication Year - 2022 (20),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Insulin Start Day - 5 (14),,,Journal - ACS Biomater Sci Eng (3),Seeding Confluency 2D (%) - 70 to 79 (6),Seeding Confluency (%) - 90 to 94 (26),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Calcium Handling Analysis Method - Rare (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Sarcomere Length (um) Quantiles - Q1 (>1.95 and ≤2.5) (13),hiPSC Backbone Media - Essential 8 (82),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Pharmacological Intervention - Class III Antiarrhythmics (K+ Channel Blockers - Prolong Repolarization) (10),Insulin Withdrawal Duration (days) - 4 days (18),Cell Line - IMR90 (19),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Pharmacological Intervention - Other Antiarrhythmic Agents (13),Action Potential Conduction Velocity (cm/s) Quantiles - Q2 (>16 and ≤28.5) (6),Journal - Tissue Eng Part A (4),,,Journal - Sci Adv (3),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),,3D Endothelial Cell Source - Rare (3),3D Stromal Cell Source - Human Fibroblast (38),Journal - Front Cell Dev Biol (3),,,New Media for Maturation - RPMI-1640 (30),Seeding Confluency (%) - 85 to 89 (43),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Publication Year - 2017 (43),Maturation Strategy - Other Cells (80),Publication Year - Post 2020 (122),3D Platform - Gelatin (6),Number of Cell Lines - 4 (11),Cell Coculture - Stromal Cell (78),Pharmacological Intervention - Thalidomide (3),Journal - Acta Biomater (10),Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),Coating for Replating - Rare (6),Wnt Inhibitor - IWR (56),Pharmacological Intervention - Lidocaine (7),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Number of Cell Lines - 4 (11),hiPSC Backbone Media - StemFlex (5),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Insulin Start Day - 11 (3),Gene Analysis Method - Rare (5),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),3D Stromal Cell Source - hiPSC-SmoothMC (3),,Wnt Inhibitor - bFGF (8),Cell Line - iCell2 (8),Insulin Start Day - 3 (5),Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),hiPSC-CM Media Supplement - Selenium (7),3D CM Ratio (CM-EC-SC) Quantiles - Q2 (>75 and ≤91) (28),Pharmacological Intervention - Thalidomide (3),3D Endothelial Cell Source - hiPSC-EndothelialC (16),,hiPSC-CM Maturation Media - Cor.4U Complete (6),hiPSC-CM Purification Duration (days) - 3 days (13),hiPSC-CM Media Supplement - Mercaptoethanol (10),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),Cell Line - BJ1 (7),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Maturation Strategy - ECM (21),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Number of Cell Lines - 3 (29),hiPSC-CM Backbone Media - Rare (10),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),hiPSC-CM Backbone Media - Rare (10),hiPSC-CM Media Supplement - iCell Maintenance Medium (41),Wnt Inhibitor - XAV939 (24),2D Surface - ECM-coated (115),Journal - Biomaterials (16),Contractile Analysis Method - Motion Tracking (93),Journal - Sci Rep (24),Wnt Inhibitor - KY02111 (7),Publication Year - Post 2020 (122),2D Surface - Microelectrode Array (9),hiPSC-CM Backbone Media - iCell Maintenance (86),hiPSC-CM Maturation Media - iCell Maintenance (83),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),3D Platform - Collagen (38),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),2D Surface - ECM-coated (115),2D Surface - Microelectrode Array (9),2D Surface - Microelectrode Array (9),Journal - Acta Biomater (10),Number of Cell Lines - 4 (11),3D Estimated Tissue Size (mm2) Quantiles - Q1 (>26.2 and ≤3500) (27),hiPSC-CM Backbone Media - iCell Maintenance (86),Seeding Confluency (%) - 70 to 79 (11),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11)
Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Contractile Analysis Method - Rare (7),3D Stromal Cell Source - hiPSC-SmoothMC (3),hiPSC Backbone Media - StemFlex (5),hiPSC-CM Purification Duration (days) - >9 days (5),Publication Year - 2017 (43),Cell Line - SCVI-273 (8),Insulin Start Day - 6 (20),Cell Line Sex - Both (118),Pharmacological Intervention - Propranolol (5),Pharmacological Intervention - Dihydropyridines (Vascular Selective Ca Channel Blockers) (22),,Pharmacological Intervention - Adrenaline (83),3D Stromal Cell Source - Dermal Fibroblast (7),,,,Publication Year - 2016 (32),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Seeding Confluency 3D (%) - 70 to 79 (3),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Journal - J Mol Cell Card (6),Disease Modelling - Specialised (3),Publication Year - 2017 (43),Differentiation Purity Assessment - IHC cTnT (7),Wnt Inhibitor - XAV939 (24),Pharmacological Intervention - Thalidomide (3),Contractile Stress (mN/mm2) Quantiles - Q1 (>3.95 and ≤50) (10),Calcium Handling Analysis Method - Rare (4),Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),Publication Year - 2017 (43),Journal - ACS Appl Mater Interfaces (4),3D Estimated Cell Density (mil cells/mL) Quantiles - Q5 (>0.01 and ≤0.47) (24),Journal - Stem Cell Res Ther (3),,,,Day of Insulin Addition - not 17 (12),Metabolic Analysis Method - Flux Rates (13),,3D Stromal Cell Source - Dermal Fibroblast (7),3D Stromal Cell Source - Stromal Cell (35),Cell Line - 201B6 (3),,,Cell Line - iCell2 (8),Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),Journal - ACS Appl Mater Interfaces (4),Metabolic Component Category - Amino Acids and Derivatives (9),3D Platform - Polyethylene Glycol (8),3D Tissue Media - DMEM (53),Insulin Withdrawal Duration (days) - 3 days (6),Journal - PLoS One (9),Day of Insulin Addition - not 10 (4),Cell Line - Cellapy (4),Seeding Confluency 2D (%) - Rare (13),3D Stromal Cell Source - Rare (4),Cell Line - Gibco episomal (10),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Cell Line Ancestry - Asian (28),2D Surface - Microelectrode Array (9),3D Tissue Media - High-glucose DMEM (9),Calcium Flux Amplitude (F/F0) Quantiles - Q3 (>0.9 and ≤1.6) (10),hiPSC-CM Media Supplement - Lipids (9),Journal - Biomaterials (16),hiPSC-CM Backbone Media - Cor.4U Complete (6),Pharmacological Intervention - E4031 (22),,Coating for Replating - Matrigel (65),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Cell Line Sex - Female (40),Wnt Inhibitor - VEGF (3),Journal - Stem Cell Res (8),Pharmacological Intervention - Thalidomide (3),hiPSC-CM Media Supplement - L-glutamine (19),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),,Number of Cell Lines - 4 (11),hiPSC-CM Maturation Media - Cor.4U Complete (6),Metabolic Component - Biotin (3),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - Circulation (11),Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Toxicological Sciences (4),Purification Protocol - Cell Sorting (7),Maturation Strategy - ECM (21),Publication Year - 2018 (45),Cell Line - iCell2 (8),Coating for Replating - Gelatin (43),Cell Line Ancestry - Caucasian (41),Action Potential Amplitude (mV) Quantiles - Q2 (>100 and ≤110) (10),Wnt Induction Duration (days) - 5 days (8),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Coating for Replating - Gelatin (43),Journal - Sci Transl Med (3),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Journal - J Tissue Eng Regen Med (3),3D Stromal Cell Source - Cardiac Fibroblast (32),2D Surface - Decellularized ECM (3),Coating for Replating - Rare (6),,,Insulin Withdrawal Duration (days) - 3 days (6),Purification Protocol - Metabolic (8),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),Sacromere or Cellular Alignment Analysis - Yes (72),3D Platform - Matrigel (33),2D Surface - ECM-coated (115),3D CM Ratio (CM-EC-SC) Quantiles - Q1 (>91 and ≤100) (74),Insulin Start Day - 5 (14),2D Surface - ECM-coated (115),Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),Publication Year - 2019 (57)
Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Disease Modelling - Genetic Disorders (18),Cell Line - Cor.4U (16),Journal - ACS Biomater Sci Eng (3),Metabolic Component Category - Metabolic Modulation (20),Calcium Flux Amplitude (F/F0) Quantiles - Q1 (>2.3 and ≤8) (10),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),,Electrophysiology Analysis Method - Patch Clamp (59),,,2D Surface - Nanotopography (6),Journal - J Mol Cell Card (6),,,,Pharmacological Intervention - Verapamil (27),Maturation Strategy - Electrical (39),3D Tissue Media - Growth Factor (12),Cell Line - WTC11 (30),Pharmacological Intervention - Blebbistatin (5),Pharmacological Intervention - Positive Inotropes (9),Cell Line - DF19-9-11T.H (16),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),,MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Wnt Induction - bFGF (45),MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Wnt Inhibitor - IWP (112),Maturation Strategy - Other Cells (80),,,,,3D Tissue Media - MEM-α (60),Coating for Replating - Fibronectin (32),,,Seeding Confluency 3D (%) - 85 to 89 (12),,,,Contraction Upstroke Velocity (um/s) Quantiles - Q4 (>1.2 and ≤10) (11),MYH7 Percentage (MYH6) Quantiles - Q2 (>30.1 and ≤82.35) (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),Journal - Cell Stem Cell (6),hiPSC-CM Media Supplement - Mercaptoethanol (10),hiPSC-CM Media Supplement - Ascorbic Acid (41),Journal - Cell Stem Cell (6),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Seeding Confluency 3D (%) - 70 to 79 (3),Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),Sacromere or Cellular Alignment Analysis - Yes (72),3D Tissue Media - iCell Maintenance (12),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),New Media for Maturation - Commercial Kit (5),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Cell Line - Gibco episomal (10),Seeding Confluency (%) - 70 to 79 (11),Seeding Confluency (%) - 90 to 94 (26),Pharmacological Intervention - Carbenoxolone (4),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),Journal - Biomaterials (16),Journal - Nano Lett (3),,Pharmacological Intervention - Class Ia Antiarrhythmics (Na+ Channel Blockers - Moderate Blockade) (8),,Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),hiPSC-CM Backbone Media - StemPro-34 (14),Pharmacological Intervention - Thalidomide (3),hiPSC-CM Media Supplement - Mercaptoethanol (10),Contractile Analysis Method - Force Transducer (27),Time from Calcium Peak to Relaxation (ms) Quantiles - Q1 (<310 and ≥0.2) (5),,MYH7 Percentage (MYH6) Quantiles - Q1 (>82.35 and ≤94.6) (4),Maturation Strategy - Mechanical (36),Coating for Replating - Vitronectin (3),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),Gene Analysis Method - RNA (169),3D Tissue Media - Growth Factor (12),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Publication Year - 2017 (43),Sarcomere Length (um) Quantiles - Q5 (>1.01 and ≤1.64) (14),2D Surface - Microelectrode Array (9),Cell Line - Cellapy (4),3D Platform - Nanotechnology (3),Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),Contractile Analysis Method - Motion Tracking (93),Insulin Start Day - 0 (7),hiPSC-CM Purification Duration (days) - 5 days (6),Insulin Withdrawal Duration (days) - 3 days (6),2D Surface - Microelectrode Array (9),Electrophysiology Analysis Method - Optical Mapping (39),Calcium Handling Analysis Method - Visual (104),,,hiPSC-CM Purification Duration (days) - 3 days (13),Wnt Induction - Rare (4),3D Stromal Cell Source - hiPSC-CardiacF (8),Electrophysiology Analysis Method - Microelectrode (31),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),2D Surface - ECM-coated (115),3D Tissue Media - MEM-α (60),Deduced Culture Strategy - 2D Only (183),Seeding Confluency 2D (%) - 70 to 79 (6),Publication Year - Post 2020 (122)
hiPSC-CM Purification Duration (days) - 6 days (10),Seeding Confluency (%) - 80 to 84 (12),Number of Cell Lines - 3 (29),Publication Year - 2017 (43),Journal - Acta Biomater (10),Insulin Start Day - 11 (3),Pharmacological Intervention - Traditional Chemotherapy Agents (18),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),,,,,Purification Protocol - Metabolic (8),Metabolic Component - IGF-1 (3),,,,Cell Line - ATCC (5),Maturation Strategy - Mechanical (36),Wnt Induction - Wnt3a (3),Seeding Confluency 2D (%) - 80 to 84 (5),2D Surface - Micropatterned (27),hiPSC-CM Backbone Media - Rare (10),New Media for Maturation - RPMI-1640 (30),hiPSC-CM Purification Duration (days) - 3 days (13),hiPSC Backbone Media - Conditioned (12),Pharmacological Intervention - Cardiotoxic Agents (3),,3D Tissue Media - Iscove (5),3D Estimated Cell Density (mil cells/mL) Quantiles - Q2 (>10 and ≤21) (17),Calcium Flux Amplitude (F/F0) Quantiles - Q2 (>1.6 and ≤2.3) (10),Cell Line - Rare (132),Wnt Inhibitor Duration (days) Quantiles - Q1 (>2 and ≤9) (58),,,,,3D Platform - 3D printed (9),hiPSC-CM Backbone Media - Commercial CM Kit (12),,,,,,,2D Surface - Microparticle/fluid (3),MYL2 Percentage (MYL7) Quantiles - Q1 (>30.1 and ≤45.7) (4),2D Surface - Nanotopography (6),Metabolic Component - Rare (4),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Maturation Strategy - Other Cells (80),Number of Cell Lines - 4 (11),Max Capture Rate of Paced CMs (Hz) Quantiles - Q1 (>2.9 and ≤6.9) (7),hiPSC Backbone Media - Conditioned (12),3D Platform - Polyethylene Glycol (8),Publication Year - 2017 (43),Differentiation Purity Assessment - Flow Cytometry VCAM1+ (4),2D Surface - Nanotopography (6),,Maturation Strategy - Cell Alignment (59),Metabolic Component Category - Signaling Pathway Regulators (6),,Insulin Start Day - 2 (4),Resting Membrane Potential (mV) Quantiles - Q4 (<-60 and ≥-66) (9),Journal - ACS Biomater Sci Eng (3),Electron Imaging - Scanning (22),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Metabolic Component - IGF-1 (3),,Purification Protocol - Metabolic (8),,Wnt Inhibitor Duration (days) - 5 days (6),Insulin Start Day - 2 (4),Pharmacological Intervention - Cardiotoxic Agents (3),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Metabolic Component - Ascorbic Acid (3),,,Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Differentiation Purity (%) Quantiles - Q4 (>79 and ≤85) (40),3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),Wnt Inhibitor - IWP (112),Publication Year - 2017 (43),Purification Protocol - Cell Sorting (7),New Media for Maturation - Rare (4),Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),Seeding Confluency 3D (%) - 85 to 89 (12),Number of Cell Lines - >5 (9),Cell Line - Cor.4U (16),3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),2D Surface - ECM-coated (115),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),hiPSC-CM Purification Duration (days) - 5 days (6),hiPSC-CM Purification Duration (days) - >9 days (5),hiPSC-CM Purification Duration (days) - >9 days (5),Journal - Cell Rep (6),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Publication Year - 2020 (51),Publication Year - 2019 (57),Number of Cell Lines - >5 (9),,,hiPSC-CM Backbone Media - Commercial CM Kit (12),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Electrophysiology Analysis Method - Microelectrode (31),Coating for Replating - Matrigel (65),Contractile Analysis Method - Traction Force Microscopy (9),Calcium Handling Analysis Method - Visual (104),Publication Year - 2021 (43),Journal - Stem Cell Res Ther (3),,Publication Year - 2019 (57),Sacromere or Cellular Alignment Analysis - Yes (72)
Publication Year - 2021 (43),hiPSC Matrix Coating - EBs (18),Disease Modelling - Hypertrophic Cardiomyopathy (6),Day of Insulin Addition - not 21 (14),3D Estimated Tissue Size (mm2) Quantiles - Q2 (>9.12 and ≤26.2) (26),Disease Modelling - Dilated Cardiomyopathy (6),Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),,,,,,Wnt Inhibitor - VEGF (3),,,,Wnt Inhibitor Duration (days) - 3 days (17),Maturation Strategy - Tension (64),Contractile Force (mN) Quantiles - Q4 (>0.04 and ≤0.16) (10),New Media for Maturation - F12 (7),Pharmacological Intervention - T3 (3),Metabolic Component - Palmitic Acid (11),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),Pharmacological Intervention - Metoprolol (5),Contractile Force (mN) Quantiles - Q5 (>0 and ≤0.04) (10),Purification Protocol - Metabolic (8),,Wnt Induction Duration (days) Quantiles - Q1 (>2 and ≤5) (61),3D Tissue Media - Commercial Kit (21),Insulin Start Day - 4 (11),,Differentiation Purity Assessment - IHC a-actinin (8),,,,,hiPSC-CM Backbone Media - Rare (10),3D Platform - 3D printed (9),,,,,,,Coating for Replating - Rare (6),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),Differentiation Purity Assessment - Visual Inspection (6),Cell Line - DF19-9-11T.H (16),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Publication Year - 2016 (32),TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Journal - ACS Biomater Sci Eng (3),Maturation Strategy - Mechanical (36),Insulin Withdrawal Duration (days) Quantiles - Q2 (>2 and ≤4) (25),Seeding Confluency (%) - 85 to 89 (43),Resting Membrane Potential (mV) Quantiles - Q1 (<-78 and ≥-85) (12),Publication Year - 2018 (45),,Differentiation Purity Assessment - IHC cTnT (7),3D Platform - Polyethylene Glycol (8),,3D Endothelial Cell Source - Umbilical Vein EndothelialC (10),hiPSC Matrix Coating - Vitronectin (10),Journal - Biomater Sci (7),3D Endothelial Cell Source - hiPSC-EndothelialC (16),Publication Year - 2014 (3),Contractile Force (mN) Quantiles - Q1 (>1.04 and ≤20) (10),,Cell Line - iCell (47),,Publication Year - 2017 (43),Wnt Inhibitor - bFGF (8),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),Journal - Nat Biomed Eng (5),Wnt Induction Duration (days) - 4 days (15),,,Journal - Stem Cell Res Ther (3),Wnt Induction - Rare (4),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),Sacromere or Cellular Alignment Analysis - Yes (72),Wnt Inhibitor - Wnt-C59 (30),,Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),,Gene Analysis Method - Rare (5),Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),Journal - Sci Rep (24),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),Journal - Nat Commun (13),Number of Cell Lines - >5 (9),,Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Journal - Tissue Eng Part C Methods (6),Wnt Inhibitor - BMP4 (7),Journal - Cell Rep (6),Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Publication Year - 2016 (32),Electrophysiology Analysis Method - Genetic (3),,,Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),,Differentiation Purity Assessment - IHC a-actinin (8),Number of Cell Lines - 4 (11),Coating for Replating - Gelatin (43),,Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),,,Cell Area (um2) Quantiles - Q3 (>350 and ≤1800) (13),3D Tissue Media - Commercial Kit (21)
Calcium Handling Analysis Method - Visual (104),Wnt Inhibitor Duration (days) Quantiles - Q3 (>1 and ≤1) (108),Electron Imaging - Transmission (62),Day of Insulin Addition - not 20 (15),Fatty Acid Metabolism Assessed - Yes (20),,2D Surface - Microelectrode Array (9),Seeding Confluency (%) - 70 to 79 (11),,,,,,Cell Coculture - Endothelial Cell (35),,,,Metabolic Analysis Method - Seahorse (35),3D Tissue Media - High-glucose DMEM (9),Cell Line - 201B6 (3),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),,hiPSC-CM Purification Duration (days) - 6 days (10),Electrophysiology Analysis Method - Genetic (3),Insulin Withdrawal Duration (days) Quantiles - Q1 (>4 and ≤10) (11),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),,Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Disease Modelling - Genetic Disorders (18),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q3 (>1.5 and ≤8.53) (5),,Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),,,,,3D Stromal Cell Source - Human Fibroblast (38),,,,,,,,Journal - Circ Res (5),Cell Line - BJ1 (7),New Media for Maturation - Rare (4),Sarcomere Length (um) Quantiles - Q4 (>1.64 and ≤1.75) (14),Maturation Strategy - Mechanical (36),Journal - Lab Chip (4),,Journal - J Mol Cell Card (6),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Differentiation Purity Assessment - IHC cTnT (7),,Maturation Strategy - Electrical (39),MYL2 Percentage (MYL7) Quantiles - Q2 (>1.2 and ≤30.1) (4),,Seeding Confluency 2D (%) - 95 to 100 (6),3D EC Ratio (CM-EC-SC) Quantiles - Q2 (>0 and ≤0) (119),,,Publication Year - 2019 (57),3D Estimated Cell Density (mil cells/mL) Quantiles - Q1 (>21 and ≤150) (24),Wnt Inhibitor - IWP (112),hiPSC-CM Media Supplement - bFGF (3),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9),,Action Potential Conduction Velocity (cm/s) Quantiles - Q3 (>10.75 and ≤16) (8),,,Pharmacological Intervention - Caffeine (4),,Day of Insulin Addition - not 22 (12),Metabolic Component - Rare (4),,,Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Cell Line - Rare (132),Journal - Tissue Eng Part A (4),3D Tissue Media - Commercial Kit (21),Action Potential Amplitude (mV) Quantiles - Q3 (>97 and ≤100) (10),,Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),,Time to Calcium Flux Peak (ms) Quantiles - Q2 (<200 and ≥154) (9),Insulin Start Day - 11 (3),Differentiation Purity Assessment - Visual Inspection (6),Cell Line - iCell2 (8),Sarcomere Length (um) Quantiles - Q2 (>1.88 and ≤1.95) (14),hiPSC-CM Media Supplement - GlutaMax (8),,Journal - Cell Rep (6),Journal - Tissue Eng Part C Methods (6),3D Endothelial Cell Source - Rare (3),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Purification Protocol - Metabolic (8),Differentiation Purity Assessment - Flow Cytometry SIRPA+ (4),Wnt Inhibitor - Others (9),Purification Protocol - Metabolic (8),,,,,Publication Year - Post 2020 (122),Insulin Start Day - 4 (11),Electron Imaging - Transmission (62),,Deduced Culture Strategy - 2D Only (183),,,New Media for Maturation - F12 (7),Maturation Strategy - Tension (64)
hiPSC-CM Media Supplement - GlutaMax (8),,Day of Insulin Addition - not 9 (3),hiPSC-CM Backbone Media - DMEM (18),,,Pharmacological Intervention - Other Antiarrhythmic Agents (13),Seeding Confluency 3D (%) - 80 to 84 (5),,,,,,Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),,,,Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),Time from Calcium Peak to Relaxation (ms) Quantiles - Q2 (>1000 and ≤310) (6),Maturation Strategy - Electrical (39),Purification Protocol - Metabolic (8),,Wnt Inhibitor - Wnt-C59 (30),Day of Insulin Addition - not 17 (12),hiPSC-CM Purification Duration (days) - 8 days (4),Maturation Strategy - ECM (21),Pharmacological Intervention - Blebbistatin (5),,Action Potential Amplitude (mV) Quantiles - Q1 (>110 and ≤170) (10),Journal - Sci Transl Med (3),,,Action Potential Conduction Velocity (cm/s) Quantiles - Q4 (>2.5 and ≤10.75) (7),,,,,Journal - Sci Rep (24),,,,,,,,Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),Publication Year - 2014 (3),3D Platform - Polyethylene Glycol (8),Pharmacological Intervention - Caffeine (4),Sarcomere Length (um) Quantiles - Q3 (>1.75 and ≤1.88) (13),hiPSC-CM Media Supplement - Transferrin (11),,Maturation Strategy - Metabolic (33),Calcium Flux Amplitude (F/F0) Quantiles - Q5 (>0.03 and ≤0.25) (11),Insulin Start Day - 9 (10),,Seeding Confluency (%) - 85 to 89 (43),Disease Modelling - Fibrotic (4),,Pharmacological Intervention - Propranolol (5),Seeding Confluency 3D (%) - 80 to 84 (5),,,3D Platform - Matrigel (33),Electrophysiology Analysis Method - Genetic (3),Coating for Replating - Vitronectin (3),Journal - Stem Cells (11),Sacromere or Cellular Alignment Analysis - Yes (72),,hiPSC-CM Media Supplement - Albumin (28),,,Purification Protocol - Cell Sorting (7),,,Metabolic Component - KOSR (3),,,Insulin Start Day - 2 (4),Journal - Biosens Bioelectron (4),Cell Line Sex - Male (64),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Pharmacological Intervention - Class Ib Antiarrhythmics (Na+ Channel Blockers - Weak Blockade) (9),,,,3D Platform - Gelatin (6),hiPSC-CM Media Supplement - Lipid Mix (5),Cell Line Ancestry - Asian (28),Cell Line Ancestry - Asian (28),,hiPSC-CM Maturation Media - Cor.4U Complete (6),,Journal - Sci Rep (24),Maturation Strategy - Mechanical (36),Coating for Replating - Gelatin (43),3D Endothelial Cell Source - Cardiac Microvascular EndothelialC (5),Publication Year - Post 2020 (122),Wnt Inhibitor - Others (9),,2D Surface - ECM-coated (115),,,,,3D Tissue Media - iCell Maintenance (12),New Media for Maturation - Rare (4),hiPSC-CM Backbone Media - Cor.4U Complete (6),,Journal - Stem Cell Res Ther (3),,,hiPSC-CM Media Supplement - bFGF (3),Resting Membrane Potential (mV) Quantiles - Q5 (>-35 and ≤-60) (9)
Resting Membrane Potential (mV) Quantiles - Q2 (<-74 and ≥-78) (8),,Day of Insulin Addition - not 18 (10),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),,,hiPSC-CM Media Supplement - VEGF (4),Cell Area (um2) Quantiles - Q2 (>1800 and ≤2850) (10),,,,,,Metabolic Component - Dexamethasone (7),,,,,Insulin Start Day - After 11 (7),hiPSC Backbone Media - Conditioned (12),Cell Line - Cellapy (4),,TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),Gene Analysis Method - RNA (169),Seeding Confluency 2D (%) - 85 to 89 (26),Action Potential Conduction Velocity (cm/s) Quantiles - Q1 (>28.5 and ≤41) (7),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),,Journal - Biomater Sci (7),,,,,,,,,Seeding Confluency 3D (%) - 85 to 89 (12),,,,,,,,Seeding Confluency 2D (%) - 95 to 100 (6),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Contractile Analysis Method - Rare (7),Seeding Confluency 2D (%) - 90 to 94 (12),Wnt Induction Duration (days) - 4 days (15),hiPSC-CM Media Supplement - Lipids (9),,Pharmacological Intervention - β-Adrenergic Antagonists (β-Blockers) (18),Journal - Sci Transl Med (3),hiPSC-CM Maturation Media - Commercial Kit (27),,Cell Line - iCell (47),3D Tissue Media - High-glucose DMEM (9),,Differentiation Purity Assessment - Flow Cytometry a-actinin+ (9),Differentiation Purity (%) Quantiles - Q2 (>90 and ≤95) (27),,,TNNI3 Percentage (TNNI1) Quantiles - Q1 (>16.15 and ≤26) (4),Differentiation Purity Assessment - Flow Cytometry cTnI+ (3),3D Stromal Cell Source - hiPSC-SmoothMC (3),Journal - Circulation (11),,,New Media for Maturation - F12 (7),,,T-tubule Structure (Found) Quantiles - Q1 (Yes) (18),,,Journal - Stem Cells Int (3),,,Journal - Sci Transl Med (3),,,,3D Estimated Cell Density (mil cells/mL) Quantiles - Q4 (>0.47 and ≤5) (25),,,,Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Journal - Int J Mol Sci (3),2D Surface - Microelectrode Array (9),2D Surface - Microelectrode Array (9),,Coating for Replating - Rare (6),,Number of Cell Lines - 2 (50),Cell Line - Cellapy (4),Day of Insulin Addition - not 19 (9),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),Differentiation Purity Assessment - IHC a-actinin (8),Deduced Culture Strategy - 2D Only (183),,Cell Line Ancestry - Caucasian (41),,,,,Electrophysiology Analysis Method - Patch Clamp (59),,Calcium Handling Analysis Method - Visual (104),,,,,Metabolic Component - Albumax (3),3D Platform - Fibronectin (3)
3D SC Ratio (CM-EC-SC) Quantiles - Q1 (>10 and ≤50) (47),,,Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),,,hiPSC Matrix Coating - Vitronectin (10),Gene Analysis Method - RNA (169),,,,,,Cell Line - BJ1 (7),,,,,3D Tissue Media - Iscove (5),Cell Line - C25 (6),Metabolic Analysis Method - Flux Rates (13),,Journal - PLoS One (9),Maturation Strategy - Elastomeric (33),Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),,Contractile Force (mN) Quantiles - Q3 (>0.16 and ≤0.43) (9),,Calcium Handling Analysis Method - Visual (104),,,,,,,,,Metabolic Analysis Method - Flux Rates (13),,,,,,,,Purification Protocol - Cell Sorting (7),3D Estimated Tissue Size (mm2) Quantiles - Q5 (>0.01 and ≤0.13) (28),Pharmacological Intervention - Propranolol (5),Seeding Confluency (%) - 80 to 84 (12),hiPSC-CM Media Supplement - Nonessential Amino Acids (8),Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),,Journal - J Mol Cell Cardiol (4),Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q2 (>8.53 and ≤17) (4),Time to Calcium Flux Peak (ms) Quantiles - Q1 (<154 and ≥0.06) (10),,New Media for Maturation - DMEM (21),,,Publication Year - 2018 (45),hiPSC-CM Purification Duration (days) - 5 days (6),,,,Seeding Confluency 3D (%) - 85 to 89 (12),,,,,Cell Line - BJ1 (7),,,,,,Contractile Force (mN) Quantiles - Q2 (>0.43 and ≤1.04) (10),,,Journal - Sci Adv (3),,,,Wnt Inhibitor - XAV939 (24),,,,Purification Protocol - Cell Sorting (7),hiPSC-CM Media Supplement - Selenium (7),Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Journal - Front Cell Dev Biol (3),,hiPSC-CM Media Supplement - Nonessential Amino Acids (8),,,Maturation Strategy - Other Cells (80),Purification Protocol - Antibiotic (4),,2D Surface - Microelectrode Array (9),2D Surface - Decellularized ECM (3),,Wnt Induction - Rare (4),,,,,Maturation Strategy - Cell Alignment (59),,,,,,,Metabolic Component - Insulin-Transferrin-Selenium (3),
Pharmacological Intervention - Blebbistatin (5),,,Differentiation Purity Assessment - Visual Inspection (6),,,Electrophysiology Analysis Method - Motion-Contrast Reconstruction (5),Differentiation Purity (%) Quantiles - Q3 (>85 and ≤90) (34),,,,,,Calcium Flux Amplitude (F/F0) Quantiles - Q4 (>0.25 and ≤0.9) (10),,,,,Disease Modelling - Fibrotic (4),hiPSC-CM Purification Duration (days) - 6 days (10),hiPSC-CM Maturation Media - Cor.4U Complete (6),,,3D Platform - Gelatin (6),Pharmacological Intervention - Carbamylcholine (6),,,,,,,,,,,,,3D Stromal Cell Source - hiPSC-CardiacF (8),,,,,,,,,Resting Membrane Potential (mV) Quantiles - Q3 (<-66 and ≥-74) (8),Differentiation Purity (%) Quantiles - Q5 (>30 and ≤79) (32),Day of Insulin Addition - not 25 (3),Calcium Handling Analysis Method - Visual (104),Wnt Inhibitor Duration (days) - 3 days (17),,,Wnt Induction Duration (days) - 5 days (8),,,,,,Time to Calcium Flux Peak (ms) Quantiles - Q3 (<254 and ≥200) (8),Contractile Stress (mN/mm2) Quantiles - Q4 (>0.07 and ≤0.51) (10),,,,Beat Rate (bpm) Quantiles - Q1 (<27.6 and ≥7) (11),,,,,,,,,,,,,,,,,,,,,,New Media for Maturation - Rare (4),Cell Line - 253G1 (10),Journal - Front Cell Dev Biol (3),Journal - Circ Res (5),,hiPSC-CM Media Supplement - HEPES (16),,,Journal - Sci Transl Med (3),,,Electrophysiology Analysis Method - Patch Clamp (59),,,Beat Rate (bpm) Quantiles - Q3 (<45 and ≥38.8) (13),,,,,,,,,,,,,
Insulin Start Day - 3 (5),,,hiPSC-CM Maturation Media - Cor.4U Complete (6),,,Differentiation Purity Assessment - Visual Inspection (6),hiPSC-CM Media Supplement - Mercaptoethanol (10),,,,,,Beat Rate (bpm) Quantiles - Q2 (<38.8 and ≥27.6) (10),,,,,Publication Year - 2020 (51),hiPSC Matrix Coating - Geltrex (33),Pharmacological Intervention - Carbamylcholine (6),,,Cell Line - WTC11 (30),Cell Line Ancestry - Asian (28),,,,,,,,,,,,,Cell Line - iCell (47),,,,,,,,,Wnt Inhibitor Duration (days) Quantiles - Q2 (>1 and ≤2) (156),,Metabolic Analysis Method - Mitochondrial (4),Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Time to Calcium Flux Peak (ms) Quantiles - Q5 (>2000 and ≤365) (10),,,,,,,,,Cell Area (um2) Quantiles - Q1 (>2850 and ≤9000) (11),,,,,Metabolic Analysis Method - Seahorse (35),,,,,,,,,,,,,,,,,,,,,,Journal - Toxicological Sciences (4),,3D Stromal Cell Source - hiPSC-CardiacF (8),Differentiation Purity Assessment - Visual Inspection (6),,Beat Rate (bpm) Quantiles - Q5 (>108 and ≤60) (12),,,3D Estimated Tissue Size (mm2) Quantiles - Q4 (>0.13 and ≤2) (31),,,Action Potential Amplitude (mV) Quantiles - Q4 (>50 and ≤97) (12),,,,,,,,,,,,,,,,
TNNI3 Percentage (TNNI1) Quantiles - Q2 (>6.5 and ≤16.15) (4),,,,,,Journal - Biomaterials (16),Journal - J Mol Cell Card (6),,,,,,Wnt Inhibitor - Rare (3),,,,,3D Tissue Media - Rare (13),Journal - J Tissue Eng (4),Cell Line Sex - Male (64),,,Journal - Stem Cells (11),Insulin Withdrawal Duration (days) - 6 days (3),,,,,,,,,,,,,Pharmacological Intervention - Doxorubicin (17),,,,,,,,,,,Wnt Inhibitor - IWP (112),3D Endothelial Cell Source - Rare (3),Insulin Start Day - 3 (5),,,,,,,,,Cell Line - Rare (132),,,,,Disease Modelling - Rare (4),,,,,,,,,,,,,,,,,,,,,,Cell Line - Cellapy (4),,Journal - Circ Res (5),,,Coating for Replating - Synthemax (3),,,Purification Protocol - Antibiotic (4),,,hiPSC-CM Maturation Media - Commercial Kit (27),,,,,,,,,,,,,,,,
,,,,,,Time to Calcium Flux Peak (ms) Quantiles - Q4 (<365 and ≥254) (11),Cell Line - ATCC (5),,,,,,,,,,,3D Platform - Nanotechnology (3),Wnt Induction Duration (days) - 3 days (38),,,,hiPSC-CM Media Supplement - B27 (180),hiPSC-CM Maturation Media - RPMI-1640 (153),,,,,,,,,,,,,Purification Protocol - Antibiotic (4),,,,,,,,,,,,,Journal - Stem Cell Res Ther (3),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2D Surface - Decellularized ECM (3),,,3D Endothelial Cell Source - Rare (3),,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,Contractile Stress (mN/mm2) Quantiles - Q2 (>1.9 and ≤3.95) (9),Journal - Circulation (11),,,,Insulin Start Day - 3 (5),Journal - Biomater Sci (7),,,,,,,,,,,,,,,,,,,,,,,,,,Journal - ACS Biomater Sci Eng (3),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,Publication Year - 2017 (43),,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,Max Capture Rate of Paced CMs (Hz) Quantiles - Q2 (>1 and ≤2.9) (8),Pharmacological Intervention - Phenylephrine (3),,,,Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),Seeding Confluency 2D (%) - 80 to 84 (5),,,,,,,,,,,,,,,,,,,,,,,,,,hiPSC-CM Maturation Media - Commercial Kit (27),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,3D Platform - 3D printed (9),,,,Wnt Inhibitor - Wnt-C59 (30),Journal - Stem Cells (11),,,,,,,,,,,,,,,,,,,,,,,,,,Contraction Upstroke Velocity (um/s) Quantiles - Q2 (>31.5 and ≤50) (10),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,Differentiation Purity Assessment - IHC a-actinin (8),Coating for Replating - Geltrex (10),,,,,,,,,,,,,,,,,,,,,,,,,,Conduction Velocity from Calcium Imaging (cm/s) Quantiles - Q1 (>17 and ≤44) (5),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,Beat Rate (bpm) Quantiles - Q4 (<60 and ≥45) (11),,,,,,,,,,,,,,,,,,,,,,,,,,,Contraction Upstroke Velocity (um/s) Quantiles - Q1 (>50 and ≤1300) (8),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
